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Chapter 1
Introduction and outline of thesis
Chapter 1
Carcinoma of the breast is world wide a frequent problem. The frequency in industrialized 
countries is, however, much higher than in less developed parts of the world. The incidence of 
breast carcinoma in the Netherlands is one of the highest in the world with 130.05 per 
100,000 females and 0.92 per 100,000 males (Dutch Cancer Registry 2008). This high 
incidence in the Netherlands may partly be caused by improved detection due to the nation­
wide breast cancer screening programme for women between the age of 50 till 75 years old, 
who are invited for a mammography every two years. Considerable improvements in the 
overall survival of breast cancer patients have been observed over the past 15-20 years due to 
the better integration of local-regional and adjuvant therapeutic modalities. This is probably 
also the reason that breast cancer is (after lung cancer) the second most common source of 
central nervous system (CNS) metastases.1 More effective treatment of primary breast cancer 
and of systemic (non-CNS) metastases of breast cancer will result in a increased number of 
patients that survive long enough to present with CNS metastases. Nowadays, all stages 
considered, approximately 75% of all breast cancer patients, can be expected to be alive ten 
years after diagnosis (Dutch Cancer Registry 2008).
In the past 5 decades a lot has changed in the treatment of breast carcinoma. Till the late 
1960s, the treatment was focussed on the locoregional situation, i.e. the involved breast and 
ipsilateral axilla. The only way tumour growth could be controlled was by removing the 
whole breast (mastectomy) and axillary lymph node dissection, often with removal of 
underlying muscle tissue (musculus pectoralis major). Some of the patients subsequently 
received chest wall irradiation.
With the increasing number of treatment modalities for breast tumours it became increasingly 
important to establish the nature of the lesion prior to surgical excision/resection. This 
information was often provided by an excisional biopsy followed by an intra-operative frozen 
section diagnosis. Awakening from the anaesthesia, the patient discovered whether the breast 
was removed (cancer) or not (benign). Another diagnostic modality was the incision biopsy: a 
piece of the tumour was removed before surgical intervention. After preparation in the 
laboratory the tissue was microscopically examined (histological examination). Later, the fine 
needle aspiration (FNA) was introduced: with a small hollow needle loose cells or small 
clusters of cells were obtained by puncturing the tumour. After laboratory processing these 
cells were microscopically assessed (cytological examination).
The first report on the use of needle punctures is found in early Arab writings circa 1000 AD.2 
Martin and Ellis from Memorial Centre Hospital, New York, are considered to be the 
founders of modern needle aspiration techniques in the late 19th and early 20th century.2-4 
During the 1940s the interest in the thin and tick needle biopsy practice decreased after some 
reports on negative aspects of this biopsy practice.4 The pioneers in the field of aspiration 
technique and diagnosis were never confident about the diagnosis of lymph node, thyroid and 
salivary lesions. This situation led to frequent misunderstandings amongst their clinical 
colleagues who therefore considered this technique as risky and unreliable. However, in the 
Memorial Centre Hospital, they continued to use this technique, but not for thyroid and
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salivary glands lesions.4 Later on, several clinicians and pathologists revived the needle 
biopsy technique as a tool for obtaining diagnostic material, amongst them the Dutch 
hematologist Dr. Paul Lopez Cardozo who published an atlas on clinical cytology in 1954.5 A 
group at the Karolinska Hospital in Sweden, with especially Drs. Soderstrom and Zajicek, 
significantly contributed to the worldwide introduction of FNA as a diagnostic tool after the 
1960s.3
Several improvements were made allowing better cytological analyses. Particularly during the 
last three decades, the improvements of cytological examinations of breast lesions consisted 
of a) better equipment for obtaining cell material for cytological analysis; b) improved 
processing of the FNA material; c) improved staining methods of the cell material.
Ad a: The cells are aspirated by means of a hollow needle connected with a syringe. The 
diameter of the needle varies and can for instance be 0.57mm (23 gauge) or 0.72 mm (21 
gauge). With the introduction of the syringe holder the tumour could be more easily sampled 
in different directions in order to retrieve more representative cell material.6 Furthermore, the 
use of ultrasound guided FNA increased the amount of diagnostic cells from palpable breast 
lesions and enabled aspiration of non-palpable lesions.
Ad b: traditionally, the cell material, obtained with a 21-or 23 gauge needle is expelled onto 
several glass slides by the aspirator. Next the material is gently smeared with another slide in 
order to get a good morphology without introducing crush artefacts. The slides can be air- 
dried and stained with May-Grunwald Giemsa (MGG) or the slides can be fixed with alcohol 
followed by the Papanicolaou (Pap) stain. This manner of processing is called the 
conventional smear preparation (CS).
The monolayer preparation (MP) technique, also called liquid-based cytology, was introduced 
initially as an alternative for cervical smears in the 1990s.7, 8 However, many laboratories now 
also process other specimens, including FNA cytology, using this technology.9 Automated 
devices, such as the ThinPrep processor, are readily available, but manual liquid-based 
techniques are less expensive and provide similar quality.10, 11 Our pathology department 
introduced the manual MP technique, employing the Hettich cytocentrifuge (synonym: 
cytospin procedure). In this procedure, the aspirated cells are fixed in alcohol and centrifuged 
in a Hettich Rotina 48S® or Hettich Rotanta 46S® centrifuge (Andreas Hettich GmbH & 
Co.KG, Tiittlingen, Germany).12 After discarding the supernatant the mixture is dripped into 
a bucket and clasped on a slide, creating a monolayer arrangement of cells within a 12 mm 
diameter area. The MP slides are Papanicolaou-stained. The procedure is described in more 
detail in chapter 2. The advantages of the MP technique approach are uniform aspirate 
processing with enhanced morphology, an increased number of all cells for microscopic 
evaluation, and the cells are deposited in a limited area on a single slide which means 
reduction of the screening time.13
Ad c: the conventional May-Grunwald Giemsa (MGG) and Papanicolaou stainings were 
improved by relatively subtle changes in the composition of these stainings. The
11
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morphological analysis of the cytological specimen is now often supplemented by 
immunocytochemical staining. Additionally molecular analysis is increasingly used in 
diagnostic pathology to improve the detection of malignancy in FNAs.14 The value of 
immunocytochemistry and molecular analysis are beyond the scope of this thesis.
The consensus recommendations for breast FNA as developed and approved by the National 
Cancer Institute (NCI)-sponsored conference approach in 1996 define the FNA as a reliable 
and efficient diagnostic tool for breast lesions when performed according to the protocol by 
experienced different disciplines (pathology, surgery, radiology).15 These recommendations 
were also formulated in order to asses the position of the breast FNA facing the increasing use 
of core needle biopsies (CNB), generally using a 14 gauge needle (i.e. 1.6 mm), in breast 
lesions as a first-line diagnostic modality in the diagnostic work-up of palpable and non- 
palpable breast lesions. A major advance of the CNB is that the resulting histology is 
generally more easy to interpret than cytological specimen and therefore can be interpreted by 
virtually any board-certified pathologist.16
In the NCI protocol, the FNA diagnoses are classified into one of 5 diagnostic categories: 
malignant (C5): cellular findings are diagnostic of malignancy, if  possible it should be further 
characterized with the specific type of neoplasm; suspicious for malignancy (C4): the cellular 
findings are highly suggestive of malignancy; atypical/indeterminate (C3): the cellular 
findings may be atypical but are not diagnostic; benign (C2): no evidence of malignancy; 
inadequate (C1): due to scant material, artefact, obscuring blood or inflammation or 
otherwise.15
The studies presented in this thesis focus on the contribution of cytological examination in the 
diagnostic work-up and management of patients with breast lesions, especially for a 'same- 
day breast clinic', and on the value of cytological examination of the cerebrospinal fluid in 
order to detect central nervous system metastases in patients with breast carcinoma presenting 
with neurological symptoms.
12
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In 1997 the monolayer preparation technique (MP) was introduced for FNA of breast lesions 
in our department. In chapter 2 the conventional smear (CS) method was compared with the 
MP technique of breast FNA, employing the Hettich centrifuge.10, 12 The FNA diagnoses were 
classified into one of the 5 diagnostic categories as proposed by the 1996 National Cancer 
Institute (NCI)-sponsored conference approach.15 The reference standard was the histological 
follow-up. A conclusive FNA diagnosis was defined 'benign' on FNA as well as in the 
histological follow-up, or 'malignant' on FNA as well as in the histological follow-up. In this 
retrospective study the results of aspirates processed by CS and by MP were compared in 
different cohorts of patients.
According to the literature in 7 to 32% of cases an inconclusive FNA diagnosis (C1, C3 and 
C4) on breast lesions is given.17-19 In those cases a repeat FNA or a core needle biopsy (CNB) 
will generally be performed in order to get a more definitive preoperative diagnosis. The 
objective of the study in chapter 3 was to compare the results of repeat FNA and CNB with 
regard to their ability to provide a clinically more useful diagnosis after a first inconclusive 
breast FNA result.
Nipple discharge (ND) is the third most frequent complaint of patients visiting a breast clinic. 
20-22 To the public ND is some sort of alarm announcing breast cancer.22, 23 In many centres 
smears of ND are performed for it is easily to obtain and it may reveal a carcinoma of the 
breast. In chapter 4 a retrospective study was performed to elucidate the diagnostic 
significance of the colour and the cytological examination of ND with a minimal follow-up 
period of 2 years. Some authors reported higher malignancy rates in bloody ND, whereas 
others found no association.22-26 We investigated the correlation of the colour (esp. bloody vs. 
white) of the ND with the histological diagnosis and whether the latter is more accurate than 
the cytological examination of ND.
In the Netherlands the incidence of breast carcinoma in males is 0.92 per 100,000 (Dutch 
Cancer Registry 2008). In chapter 5 the value of the FNA in the work-up of male breast 
lesions was determined in comparison with histological analysis over a period of 15 years. 
The results were compared with studies in the recent literature.27-29
Many laboratories replaced FNA by CNB. The histological diagnosis based on CNB gained 
importance in the initial diagnostic work-up for it can provide more information about the 
tumour characteristics such as precise type of carcinoma, hormonal receptor status and other 
molecular features.30 Subsequently, some laboratories introduced core wash (CW) or touch 
imprint (TI) cytology from the CNB, aiming at a quick preliminary diagnosis that contributes 
to efficient management of the 'same-day breast clinic' and for alleviating patient anxiety.31-35 
Contradictory results of both techniques in the literature led to our preclinical study
31 33 36 39investigating an alternative modified method of TI and CW cytology (chapter 6). - , - 
Fresh breast specimens (mastectomy, lumpectomy), obtained after surgery were biopsied by a 
core needle in a laboratory setting. With the modified technique TI and CW slides were made,
O u t l i n e  o f  t h e s i s
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and categorized as malignant (C5), suspicious for malignancy (C4), atypical (C3), benign 
(C2) and inadequate (C1), and the results were compared with the histologic CNB results.15
The first results obtained in the clinic by CW cytological diagnosis in breast cancer patients 
are presented in chapter 7. The results of the CW cytology and CNB histology were 
correlated with the histopathology of subsequently obtained resection specimens and 
sensitivity and specificity of CW cytology was calculated.
Breast cancer is (after lung cancer) the second most common source of central nervous system 
(CNS) metastases. The incidence given varies between 3% to 15%.1, 40-44 More effective 
treatment of primary breast cancer and of systemic (non-CNS) metastases of breast cancer 
will result in an increase in number of patients that survive long enough to present with CNS 
metastases.1, 44-48 The neurological signs and symptoms of CNS metastases are widely 
variable and generally caused by increased intracranial pressure or neurological dysfunction 
due to local effect of the tumour. The neuroradiological findings are very divergent as well. 
Proof of metastatic disease in/around the CNS is important for rational therapeutic decision 
making (e.g. systemic and/or intrathecal chemotherapy, radiotherapy, wait and see policy). 
Cytology of cerebrospinal fluid (CSF) obtained by a lumbar puncture is generally considered 
as a quick, relatively easy, minimally invasive and inexpensive method to prove the presence 
or absence of metastatic spread to the CNS. In chapter 8 the value of a CSF cytological 
diagnosis in breast cancer patients presenting with neurological signs and/or symptoms 
suspected for metastatic spread to the CNS were assessed. The results of cytological analysis 
of CSF were in this retrospective study compared with the clinical, neuroradiological, and 
survival data of these patients.
14
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The role of laboratory processing in determining diagnostic 
conclusiveness of breast fine needle aspirations: 
conventional smearing versus a monolayer preparation
C.A.P. Wauters, B.W. Kooistra, L.J.A. Strobbe
J Clin Pathol 2009 62: 931-934
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ABSTRACT
Background
To compare breast fine needle aspiration (FNA) specimens prepared by conventional 
smearing (CS) versus monolayer preparation (MP), with respect to the conclusiveness of the 
cytopathological diagnosis.
Methods
From 1992 to 1996, aspirators prepared aspirates themselves by direct smearing onto 2-4 
slides. From 1999 to 2003, aspirate preparation was performed in the laboratory, creating a 
MP, using a Hettich cytocentrifuge. FNA diagnoses were categorised into inadequate (C1), 
benign (C2), atypical (C3), suspicious for malignancy (C4) and malignant (C5). The 
reference standard constituted histological follow-up. A conclusive FNA diagnosis was 
defined as C2 in lesions benign on follow-up and C5 in lesions malignant on histology.
Results
From 1992 to 1996, 692 aspirates were processed by CS, whereas from 1999 to 2003, 
1301 aspirates were processed by MP. More FNA were ultrasound-guided in the MP group 
(85.6% versus 21.5%, p<0.001). When compared with CS, MP-prepared FNA had conclusive 
diagnoses significantly more often (72.8% versus 58.5%, p<0.001). This effect remained 
significant when corrected for the difference in ultrasound guidance (adjusted odds ratio 1.7, 
95% confidence interval 1.3 to 2.2, p<0.001), and was larger for malignant lesions than for 
benign lesions (51.7% versus 79.9%, p<0.001).
Conclusion
Patients presenting with breast lesions can more often be offered a same-day, conclusive 
cytopathological diagnosis when FNA are prepared by a manual MP processing technique.
20
CS versus MP
The primary aim in same-day breast cancer diagnosis is integration of imaging, clinical 
investigation and cytological confirmation within 1 day. Consequently, it is important to 
minimise the number of inconclusive fine-needle aspiration (FNA) results. Liquid-based 
preparation of aspirates has been gaining popularity since its launch in the early 1990s. It has 
proven cost effective and time saving when compared with conventional smear (CS) 
preparation in gynaecological1,2 and non-gynaecological3 cytology. More important, it offers 
uniform aspirate processing, possibly decreasing the number of inadequate FNA, and thus 
precluding expansion of the diagnostic investigation.4
Technically, a liquid-based preparation differs from a CS in that the aspirate is immediately 
fixed and centrifuged and that cells end up on a limited area on a single slide. This implies a 
shorter screening time,5 and also a change in cytological interpretation. Compared with CS, 
liquid-based preparations increase cellularity6 and enhance cellular morphology.5 
While automated devices, such as the ThinPrep processor, are readily available, manual 
liquid- based techniques are less costly and might there- fore prove a sensible alternative.7 
In this paper, we report on our diagnostic experience with a manual monolayer preparation 
(MP) of breast FNA, employing the Hettich cytocentrifuge.
The present study aimed to evaluate the rates of conclusive diagnoses established by FNAs 
prepared by MP as compared with CS. Using retrospective data on 1993 cases, we 
hypothesised that breast FNA would be diagnosed conclusively more frequently when the 
aspirate was prepared by MP.
METHODS 
Data collection
This retrospective study was performed on consecutive FNAs taken from palpable and non- 
palpable breast lesions in a regional teaching hospital, followed by a histological 
diagnosis. Data were extracted from the prospective national pathology database of The 
Netherlands.
Cytology specimens were obtained by radiologists using ultrasound guidance, and by 
surgeons using freehand aspiration. Either a 21 gauge or a 23 gauge needle was used for 
aspiration, and this was random for both CS-prepared and MP- prepared aspirates. No 
retrospective data on the aspirator’s skill were available. Following excisional biopsy, tumour 
size was measured by pathologists, and the histological grade of malignant lesions according 
to the modified Bloom-Richardson classification8 was determined.
Laboratory processing
CS and MP samples were processed in the same laboratory. CS preparation was routinely 
used from 1992 to 1996. From then, it was gradually replaced by MP, giving 
cytotechnologists and pathologists time to gain experience. From mid- 1998, MP became the 
only method used. Therefore FNAs taken in 1997 and 1998 were excluded from this study, 
thereby skipping the learning curve.
INTRODUCTION
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Conventionally prepared specimens included direct smears for solid masses and 
cytospins (Thermo Fisher Scientific, Waltham, Massachusetts, USA) for fluids. For CS, 
the aspirate was smeared by the aspirator onto as many slides as were needed to allow a 
complete image of the specimen (ie, 2-4 slides) and instantly fixated in 95% ethanol. This 
allowed for immediate cytological examination when the slides arrived in the laboratory.
As for MP, the aspirator had no role in the cytological preparation. Once arrived in the 
laboratory, cells were rinsed from the needle and syringe into a vial and directly fixed in 
a 50% ethanol, 2% polyethylene glycol solution. The mixture was centrifuged for 10 min at 
688 rpm in a Hettich Rotina 48S or Hettich Rotanta 46S cytocentrifuge (Andreas 
Hettich, Tuttlingen, Germany).9,10 The supernatant was discarded. Depending on the 
estimated density of the sediment, one or two drops of the 50% ethanol, 2% polyethylene 
glycol solution was added. The resultant mixture was dripped into a bucket that was clasped 
on a poly-L-lysine slide (Menzel, Braunschweig, Germany). By centrifuging for 5 min at 688 
rpm, the sediment was pressed onto the slide, creating a monolayer arrangement of all cells 
within a 12 mm diameter area. Only one MP slide per aspirate was prepared.4 In case of 
a haemorrhagic aspirate, an additional slide was prepared by lysing erythrocytes with 2.5% 
acetic acid. CS and MP slides were stained with Papanicolaou stain.
FNA examination and histology
Slides were screened by cytotechnologists and examined by 10 staff cytopathologists with 
6-20 years of experience in cytopathology. Using simple and well-defined criteria,11 
they classified each aspirate into one of five diagnostic categories: inadequate (C1), benign 
(C2), atypical (C3), suspicious for malignancy (C4) and malignant (C5).12 A conclusive 
FNA diagnosis was defined as a benign diagnosis (C2) in lesions that were benign on follow- 
up and as a malignant diagnosis (C5) in lesions that were malignant on follow-up. On 
occasion, clinical information regarding the breast lesion was available to the pathologists at 
the time of cytopathological examination.
Each aspirate was related to its eventual histological diagnosis. Invasive carcinoma and ductal 
carcinoma in situ (DCIS) were considered malignant. All other diagnoses were considered 
benign.
Statistics
The relationship between the method of preparation (CS versus MP) and diagnostic 
conclusiveness was described with an odds ratio (OR) and was corrected for the effect of 
possible confounders by logistic regression. We used the X2 test for testing differences 
between proportions of FNA diagnostic categories between the CS and MP group.
We a priori planned one subgroup analysis. Since the elimination of disturbing background 
material is an important feature of MP,13 we hypothesised that the effect of MP on diagnostic 
conclusiveness would be larger in malignant lesions. We tested this with a formal test of 
interaction, using logistic regression.14
All tests were two-sided. Values of p<0.05 were considered significant. When separately 
testing proportions of FNA diagnostic categories, we adjusted the significance threshold 
to p<0.01 for multiple testing.15
22
CS versus MP
RESULTS 
Study population
From 1 January 1992 to 31 December 1996, 692 FNA were performed and subsequently 
prepared by CS. From 1 January 1999 to 31 December 2003, 1301 FNA were performed 
and prepared by MP. O f this subsequent total of 1993 lesions aspirated, 516 (25.9%) were 
benign and 1477 (74.1%) were malignant. The most frequent histological diagnoses 
included invasive ductal carcinoma (n = 1073), aspecific benign tissue (n = 241), invasive 
lobular carcinoma (n = 223) and fibroadenoma (n = 141).
Table 1 shows comparative clinical and pathological characteristics of the studied subjects. 
The only marked difference between the groups was that breast lesions in the CS group were 
significantly less likely to be aspirated under ultrasound guidance than those in the MP group.
Table 1 Key patient characteristics
Characteristic
Preparation
CS (n = 692) MP (n = 1301)
Mean age (SD), years 55.9 (14.8) 55.9 (15.0)
Malignant, % 72.7 74.9*
Mean tum our size (SD), mm 24 (17) 22 (13)*
Tum our grade, % f
Grade 1 16.2 14.8
Grade 2 44.6 44.9
Grade 3 38.8 40.0
Unknown 0.4 0.3
U ltrasound-guided FNA, % 21.5 85.6*
*p<0.05; fin  malignant tumours only; fp<0.001.
CS, conventional smear; FNA, fine needle aspiration, MP, monolayer preparation
Diagnostic conclusiveness
MP-prepared aspirates were conclusive significantly more frequently than aspirates prepared 
by CS (72.8% versus 58.5%, respectively, OR 1.9, 95% confidence interval (CI) 1.6 to 2.3, 
p<0.001; Table 2). When corrected for the effect of ultrasound guidance, a slightly weaker, 
but still highly significant, association remained (adjusted OR 1.7, 95% CI, 1.3 to 
2.2, p<0.001). This corrected beneficial effect of MP on conclusiveness was significantly 
more pronounced in malignant lesions than in benign lesions (p<0.001, Table 3).
Specifically, MP-prepared aspirates of benign lesions were significantly less often inadequate 
than were CS-prepared aspirates (18.0% versus 32.8%, respectively, p<0.001; Fig. 1).
23
Chapter 2
Table 2 Association between the method of preparation and diagnostic conclusiveness
Preparation Conclusive* Inconclusive
Controventional sm ear 58.5 41.5
M onolayer preparation 72.8 2 7 .2 |
Values are percentages.
‘ Defined as a C2 diagnosis in benign lesions and a C5 diagnosis in malignant lesions. 
f1 .9, 95% CI 1.6-2.3, p<0.001.
Malignant lesions had significantly less inadequate (4.8% versus 17.7%, respectively, 
p<0.001), less suspicious (7.2% versus 11.7%, respectively, p = 0.005), and more malignant 
FNA diagnoses (79.9% versus 63.4%, respectively, p<0.001) when the aspirate was prepared 
by MP
Table 3 Subgroup analysis of the effect of the preparation method on the diagnostic conclusiveness of fine 
needle aspiration in malignant and benign lesions
Histologic (conclusiveness)
Preparation Benign Malignant
Conventional sm ear 45.5 63.4
M onolayer preparation 51,7 79.9*
Values are percentages.
*p<0.001 for the effect of the interaction between preparation method and histology on diagnostic conclusiveness
DISCUSSION 
Key findings and limitations
The current study demonstrates that (1) breast FNAs are more conclusively diagnosed when 
processed by MP compared with CS, and (2) this benefit is most pronounced in malignant 
breast lesions. Our data show a 14.3% absolute reduction of inconclusive FNAs following MP 
adoption. This indicates that for one additional FNA to be diagnosed conclusively, seven 
aspirates should be processed by MP instead of CS (1/0.143).
The major limitation of this study lies in its retrospective nature. Certain confounding factors, 
such as differences among aspirators and variable cytopathologist experience, cannot 
be controlled for. Hence, a direct and completely fair comparison between CS and MP is 
impossible. However, we accounted for key patient and tumour characteristics affecting 
conclusiveness; these characteristics included ultrasound guidance, tumour size and tumour 
grade.16,17
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Inconclusive cytological diagnoses
Inconclusive FNA diagnoses (ie, diagnoses other than ‘benign (C2)’ in benign lesions, and 
other than ‘malignant (C5)’ in malignant lesions) are of clinical concern. These provide 
no information, delay diagnostic investigation, and require further investigations, such as core 
needle biopsies, to provide a conclusive diagnosis.18-20 Low-grade tumours and 
increased medicolegal claims are acknowledged as causes of the increased reporting of 
indeterminate diagnoses.11 Several studies have demonstrated variable conclusiveness rates 
for CS, ranging from 54% to 87%.21-24 As for MP, conclusiveness rates of 73-77% have been 
reported for breast FNAs processed by MP.7,25 Our results correspond well with these findings 
(Table 2). Liquid-based preparation techniques, such as ThinPrep, have received considerable 
attention because of their favourable results with respect to cytomorphology and diagnostic 
conclusiveness.5,13,24 In direct comparisons with CS, ThinPrep has been shown to yield 
superior conclusiveness in gynaecological,3,26 general non- gynaecological3 and breast 
lesions.24 However, no direct comparisons of CS and MP preparations with regard to validity 
have been performed. In a paired comparison of 44 breast lesions, Florentine et al found CS 
and MP to yield similar cytological diagnoses, correlating in 41 cases.25 However, FNA 
results were not correlated with histology.
Figure 1 Frequencies of fine needle aspiration (FNA) diagnoses of aspirates prepared by conventional smearing 
(CS) and by a monolayer preparation (MP), in benign and malignant breast lesions. Data are presented as means 
and 95% confidence intervals. *p<0.01 for the difference in the proportions of a diagnosis between CS and MP.
Benign lesions
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20% ii
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i l
j i i L r F r ^ i
Inadequate Benign A typ ica l S usp ic ious  M alignant 
FNA diagnosis
□  CS
□  MP
Malignant lesions
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20%
0% EL
Inadequate Benign A typ ica l S usp ic ious M alignant 
FNA diagnosis
Obviously, the laboratory preparation method is not the only determinant of whether an 
a spirate will yield a conclusive, valid diagnosis. Substantially more aspirations were 
ultrasound- guided in the MP group. Therefore, lesions in this group may have been aspirated 
more accurately.16,27 Yet, conclusiveness of MP-processed aspirates remained significantly
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higher following statistical correction for the effect of ultrasound guidance. This implies a 
genuine effect of MP on conclusiveness. Moreover, the finding of a smaller mean tumour size 
in the MP group, possibly caused by the implementation of the Dutch nationwide 
breast cancer screening programme,28 may partly counterbalance the relative beneficial effect 
of ultrasound on conclusiveness. Detection of smaller tumours may have contributed to 
increased difficulty in obtaining diagnostic aspirations in the MP group.17
Differences in preparation and cytomorphology
During MP processing, aspirated cells are centrifuged and are concentrated upon a single 12 
mm slide. This results in a higher observed cellularity, whereas in CS cells are dispersed 
over multiple slides.25,29 Additionally, liquid-based preparation comprises direct rinsing of 
cells in fixation fluid, preventing air drying artefacts and removing disturbing background 
material, both of which are frequently present in CS-prepared aspirates.30 Finally, 
conventionally smeared cells may be destroyed in the smearing process. These CS drawbacks 
are probably crucial in cases of borderline adequacy. For example, liquid-based preparations, 
including MP, remove the majority of disturbing background material such as necrotic 
debris.6,13,29 As the latter is relatively frequently present in aspirates of malignant 
lesions,31 the effect of MP may be more pronounced here. Indeed, we found that FNA 
conclusiveness increased more substantially in malignant lesions than in benign lesions 
following the implementation of MP.
Despite the potential advantages as described above, MP has potential limitations. First, MP 
of breast aspirates requires laboratory processing and therefore more time than CS. Yet, this 
difference is in the order of 20 min and should therefore not compromise the ability to provide 
a same-day diagnosis by FNA. A second potential limitation of MP is that is does not allow 
for an on-site assessment of aspirate adequacy by methods such as Diff-Quik.32 In contrast, 
this is possible for smears. Thus, FNA in the CS group may have been conclusive more often 
had every aspirate been pre-assessed for adequacy. However, routinely performing these 
assessments is costly and time consuming,33 resulting in few centres adhering to this protocol.
Conclusion
In conclusion, patients presenting with palpable and non- palpable breast lesions can more 
often be offered a same-day diagnosis when FNA are prepared by a manual MP 
processing technique. Consequently, breast clinics adhering to conventionally smeared FNA 
as a means of providing a same-day, preliminary diagnosis of breast lesions may benefit 
from switching to MP processing.
Acknowledgements: The authors would like to thank Dr Teerenstra for statistical support and 
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ABSTRACT 
Background
Fine-needle aspiration (FNA) of breast lesions provides indeterminate (C1, C3, and C4) 
diagnoses in a high proportion of cases. The aim of the present study was to retrospectively 
determine whether repeat FNA or core needle biopsy (CNB) most frequently provides a 
correct and more conclusive diagnosis.
Methods
All patients who had an indeterminate primary FNA followed by repeat FNA or CNB within 
1 month from 1992 to 2007 were included. FNA was diagnosed as C1-C5; CNB was 
diagnosed as B 1- B5. Improvement in preoperative diagnosis by repeat FNA or CNB was 
defined as C2/B2 in benign lesions, C3/B3 in premalignant lesions, C4/B4 or C5/B5 in 
malignant lesions where primary FNA was C1, and C5/B5 in malignant lesions where 
primary FNA was C3 or C4.
Results
Among 255 eligible cases, CNB improved the preoperative diagnosis more often than did 
repeat FNA (78.0% vs. 54.8%, odds ratio = 2.9, P<.001). When corrected for patient 
age, appearance on mammogram (mass or not), clinical findings (palpable or not), tumor size, 
and aspiration mode (freehand vs. image guided), this difference slightly increased 
(odds ratio = 3.0, P = .001).
Conclusion
CNB should be performed after an indeterminate FNA of a breast lesion to obtain a reliable 
and clear preoperative diagnosis.
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Fine-needle aspiration (FNA) has proven to be a reliable asset in same-day diagnosis of breast 
malignancies.1-3 Given the relative increase in nonpalpable breast lesions as a result of 
nationwide breast cancer screening, FNA carries more consequences in treatment planning 
than it did formerly. However, no definitive diagnosis can be established on the basis of 
cytology in 7% to 32% of cases.4-6 This group comprises lesions with inadequate (C1), 
atypical (C3), and suspicious (C4) FNA. Routinely, either a repeat FNA or a core needle 
biopsy (CNB) is performed to obtain a more definite preoperative diagnosis.5-7 
The objective of the current study was to compare repeat FNA and CNB with regard to their 
ability to provide a clinically more useful diagnosis after an indeterminate primary breast 
FNA.
The hypothesis was that when corrected for potential confounding variables, CNB allows for 
a true and conclusive preoperative diagnosis more often than repeat FNA. This was tested by 
multivariate logistic regression analysis of 255 cases.
MATERIALS AND METHODS 
Study Population and Data Acquisition
Data on all patients visiting the one-stop breast clinic in a regional teaching setting between 
1992 and 2007 were retrospectively collected from the Dutch national pathology database 
PALGA. Patients that had an indeterminate FNA diagnosis (C1, C3, or C4) followed by a 
repeat FNA or a CNB of the same breast lesion within 1 month were analyzed.8 The PALGA 
database and patient files were reviewed for data on patient age, aspiration mode (freehand vs. 
image guided for both FNA and CNB), tumour size, clinical findings (palpable or 
nonpalpable), type of dominant lesion on mammography (mass or not), and signs 
of ipsilateral breast cancer developing if the patient was not operated on. Nonmass 
mammographic lesions included microcalcifications and architectural distortions. 
Tumour size was measured on the surgical specimen or on ultrasound in cases where the 
patient was not operated on.9
Follow-Up
The reference standard constituted surgical specimens or clinical follow-up when no surgical 
outcome was available. Premalignant surgical lesions included atypical ductal hyperplasia, 
lobular carcinoma-in-situ, and atypical papillomatosis.
Repeat FNA and CNB
Cytologic (FNA) and histologic (CNB) material was obtained by freehand or image-guided 
needle handling. For FNA, a 21- to 23-gauge needle attached to a 20-mL syringe was used. 
FNA were diagnosed as C1, inadequate; C2, benign; C3, atypical; C4, suspicious; or C5, 
malignant.8,10 An indeterminate FNA diagnosis was defined as C1, C3, or C4. Aspirates were 
either smeared and fixed in ethanol 95% or rinsed, fixed in an ethanol 50%-polyethylene
INTRODUCTION
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glycol 2% solution, and centrifuged, creating a monolayer preparation. Both smears and 
monolayer slides were Papanicolaou stained.
CNB were performed with an 18-gauge needle mounted on an automated device (Bard 
Magnum, C. R. Bard, Covington, GA) for lesions appearing as masses on ultrasound. For 
lesions invisible on ultrasound, stereotactic vacuum-assisted CNB (Vacora, Bard Peripheral 
Vascular, Tempe, AZ) were performed with a 14-gauge needle. CNB specimens were fixed in 
formalin and stained with hematoxylin and eosin. CNB diagnostic categories included 
B1, normal tissue or unsatisfactory; B2, benign; B3, uncertain malignant potential; B4 
suspicious of malignancy; and B5, malignant.8 B3 lesions included atypical ductal 
hyperplasia, lobular carcinoma-in-situ, and atypical papillomatosis. FNA and CNB were 
examined by 12 pathologists with 11 to 20 years of experience at the beginning of the 
study period. Limited clinical information was available to pathologists when examining the 
slides.
A preoperative improvement of an indeterminate FNA diagnosis was noted when repeat FNA 
or CNB yielded a true and more conclusive diagnosis. In exceptional cases, lesions diagnosed 
as premalignant on the surgical specimen with inadequate and suspicious diagnoses on 
primary FNA and atypical diagnoses on repeat FNA or CNB were considered to have had an 
improvement in preoperative diagnosis (Table 1).
Table 1 Criteria for assigning improvement in preoperative diagnosis according to histologic nature of surgical 
specimen
Follow-up Indeterm inate diagnosis 
First FNA
Improved preoperative diagnosis 
Second FNA CNB
Benign C1, C3, C4 C2 B2
Premalignant C1, C4 C3 B3a
Malignant C1 C4, C5 B4, B5
C3, C4 C5 B5
FNA fine-needle aspiration, CNB core needle biopsy
a Includes atypical ductal hyperplasia, lobular carcinoma-in-situ, and atypical papillomatosis
Statistical Analysis
The x2 test was used for comparing proportions of diagnostic improvement between repeat 
FNA and CNB. A forced-entry logistic regression model was used for correcting this 
difference for patient age, tumour size, aspiration mode, and lesion type as assessed by 
mammogram, as well as whether or not the lesion was palpable. Differences and odds ratios 
(OR) were considered to be statistically significant at P<.05. SPSS version 15.0 (SPSS, 
Chicago, IL) was used for statistical analysis.
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RESULTS 
Patient Characteristics
From January 1, 1992, until December 14, 2007, a total of 255 FNA in 242 patients met the 
inclusion criteria. No patient received neoadjuvant therapy. Mean patient age was 55.6 years 
(standard deviation, 13.0). Follow-up was derived from the surgical specimen in 198 cases 
(median time to surgery, 5 days; range, 0-122 days) and from clinical follow-up in 57 cases 
(median duration, 43 months; range, 7-137 months). Of these latter patients, 12 had 
malignant disease, but they were not operated on because they had distant metastases (n = 3), 
refused (n = 2), or were deemed unfit for surgery (n = 5), or because the aspirated lesion was a 
metastasis from a nonmammary primary tumor (n = 2).
After the primary indeterminate FNA, 73 patients had repeat FNA and 182 patients had CNB. 
At follow-up, 87 lesions turned out to be benign, 10 were premalignant, and 158 were 
malignant.
Table 2 Univariate differences in allowance for diagnostic improvement by repeat FNA vs. CNB after an 
indeterminate primary FNA.
Second-line diagnostic modality D iagnostic improvement (%)
No Yes
FNA 45.2 54.8
CNB 22.0 78.0a
FNA fine-needle aspiration; CNB core needle biopsy 
a x2 = 13.6, P < .001
Diagnostic Improvement
CNB improved the preoperative diagnosis more often than did repeat FNA (78.0% vs. 54.8%, 
OR = 2.9, x2 = 13.6, P < .001, Table 2). When adjusted for patient age, tumour size, and 
appearance on mammogram, as well as whether or not the lesion was palpable and the 
aspiration mode of the first and second diagnostic procedures, CNB still performed better 
compared with repeat FNA (OR = 3.0, P = .001, Table 3). Logistic regression revealed no 
significant effect of any of the above parameters on improving preoperative diagnosis. There 
were no significant correlations between tumour size and clinical findings (P = .23) and 
between appearance on mammogram and clinical findings (P = .16).
DISCUSSION
The current study evaluated the optimal preoperative workup after an indeterminate (C1, C3, 
or C4) breast FNA. In patients who subsequently had CNB, preoperative diagnosis improved 
in 78.0%, compared with 54.8% for patients with repeat FNA (Table 2). This difference 
was not affected by clinical, radiologic, and histopathologic differences between these groups 
(Table 3).
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Table 3 Multivariate logistic regression analysis of factors affecting diagnostic improvement
Factor Odds ratio3 P value
Repeat FNA vs. CNB 3.0 0.001
Patient age 1.0 0.17
Palpable vs. nonpalpable 0.8 0.70
Mass vs. no mass on m ammography 0.7 0.36
Tum or size 1.0 0.90
Primary FNA, freehand vs. image guided 1.3 0.54
Repeat FNA/CNB, freehand vs. image guided 1.6 0.38
FNA fine-needle aspiration; CNB core needle biopsy
a An odds ratio of >1 indicates an increased corrected chance of improving the preoperative diagnosis when the 
covariate increases with one unit (i.e., switches from the first to the second category in case of a dichotomous 
covariate)
In general, CNB is preferred over FNA as the first-line diagnostic modality because it more 
often provides a conclusive and adequate diagnosis than FNA.4,11-13 However, other centers 
continue to use primary FNA because the predictive value of malignant FNA diagnoses 
approaches 100%, allowing for a same-day diagnosis in 49% to 90% of breast cancers.1,2,6,14 
Patients are served well when quickly informed about their diagnosis and 
treatment opportunities, but this is only possible when an unequivocal diagnosis is available 
preoperatively. Indeterminate FNA diagnoses result from sampling errors, 
interpretation errors, and possibly adverse histopathologic tumour characteristics such as a 
fibrous consistency and lobular histology.15,16
In these instances, either a repeat FNA or a CNB is routinely performed, probably varying 
with specific center protocols or radiologist preference.6,7 However, the validity of this choice 
has only been defined in small patient groups. CNB has been reported to provide clinically 
useful information in 76% to 90%, compared with 41% to 45% for repeat FNA.5,6,17 The 
present study indicates that this difference is somewhat smaller, but still evident. 
Compared with FNA, CNB needles are larger and sampling is less operator dependent.18 
Deep, desmoplastic lesions would therefore be unlikely to be aspirated successfully 
by repeating the same FNA procedure. Because most failed FNAs are the result of sampling 
error, this is probably the most important explanation of the observed difference 
in improvement of preoperative diagnosis.6,19
It is of note that CNB yielded clinically useful information in only 78%, while reported 
sensitivities and specificities are generally higher, ranging from 88% to 100% and 68% to
12,13,20,2196%, respectively. , , , This is probably the result of a selection bias created by the 
study inclusion criteria, leaving only those lesions that are hard to aspirate or whose tissue is 
hard to examine by the pathologist. This might prompt some clinicians to directly move on to 
excisional biopsy after an indeterminate FNA. Although the current study did not investigate 
this scenario, it would not be advisable. A malignant CNB may result in wider margins at 
initial excision, possibly decreasing the chance of positive resection margins, and signs of 
histopathologic invasion on CNB may preliminarily determine axillary workup (i.e., sentinel 
node biopsy or not).22,23 Furthermore, a negative CNB spares the patient unnecessary surgery, 
making it a cost-effective modality.24
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However, indeterminate diagnoses remain after CNB. An atypical CNB diagnosis (B3) would 
still seem more valuable clinically than an atypical FNA diagnosis (C3) because B3 lesions on 
CNB carry highly variable risks of malignancy on subsequent excision.25 As a 
consequence, treatment of indeterminate lesions can be more reliably tailored to the patient 
compared with situations where repeat FNA was atypical.
The present study has several limitations. Its retrospective design may not have allowed for a 
fair comparison between the repeat FNA and CNB groups. Because the study spans a long 
period of time, factors that have changed in time may have influenced diagnostic performance 
in these groups unequally. Multivariate analysis was used to minimize this potential bias. Yet 
the difference in diagnostic improvement between repeat FNA and CNB remained grossly 
unchanged between univariate and multivariate analyzes (OR = 2.9 to OR = 3.0, 
respectively; Tables 2, 3). This is rational to some extent. For instance, tumour size does not 
change from the first to the second diagnostic procedure and should therefore not affect 
better performance of one modality over the other.
Conclusion
In summary, this study indicates that a CNB should be performed after an indeterminate (C1, 
C3, or C4) FNA of a breast lesion to obtain a reliable and clear preoperative diagnosis. For 
breast clinics more heavily adhering to a same-day diagnosis, a repeat FNA may be feasible, 
but one should consider that obtaining a more conclusive diagnosis is only possible in half of 
these cases.
37
Chapter 3
REFERENCES
1. Kontzoglou K, Moulakakis KG, et al. The role of liquid-based cytology in the investigation of breast lesions 
using fine-needle aspiration: a cytohistopathological evaluation. J Surg Oncol. 2005;89:75-8.
2. Ariga R, Bloom K, Reddy VB, et al. Fine-needle aspiration of clinically suspicious palpable breast masses 
with histopathologic correlation. Am J Surg. 2002;184:410-3.
3. Thibault F, Meunier M, Klijanienko J, et al. Diagnostic accuracy of sonography and combined sonographic 
assessment and sono graphically guided cytology in nonpalpable solid breast lesions. J Clin Ultrasound. 
2000;28:387-98.
4. Duijm LE, Groenewoud JH, Roumen RM, et al. A decade of breast cancer screening in The Netherlands: 
trends in the preoperative diagnosis of breast cancer. Breast Cancer Res Treat. 2007;106:113-9.
5. Carty NJ, Ravichandran D, Carter C, et al. Randomized comparison of fine-needle aspiration cytology and 
Biopty-Cut needle biopsy after unsatisfactory initial cytology of discrete breast lesions. Br J Surg. 
1994;81:1313-4.
6. Farshid G, Rush G. The use of fine-needle aspiration cytology and core biopsy in the assessment of highly 
suspicious mammographic microcalcifications: analysis of outcome for 182 lesions detected in the setting of 
a population-based breast cancer screening program. Cancer (Cancer Cytopathol). 2003;99:357- 64.
7. Manfrin E, Mariotto R, Remo A, et al. Is there still a role for fineneedle aspiration cytology in breast cancer 
screening? Experience of the Verona Mammographic Breast Cancer Screening Program with real-time 
integrated radiopathologic activity (1999-2004). Cancer (Cancer Cytopathol). 2008;114:74-82.
8. Perry N, Broeders M, de Wolf C, et al. European guidelines for quality assurance in breast cancer screening 
and diagnosis. Fourth edition—summary document. Ann Oncol. 2008;19:614-22.
9. Shoma A, Moutamed A, Ameen M, et al. Ultrasound for accurate measurement of invasive breast cancer 
tumor size. Breast J. 2006;12:252-6.
10. The uniform approach to breast fine-needle aspiration biopsy. NIH Consensus Development Conference. 
Am J Surg. 1997; 174:371-85.
11. Lieske B, Ravichandran D, Wright D. Role of fine-needle aspiration cytology and core biopsy in the 
preoperative diagnosis of screen-detected breast carcinoma. Br J Cancer. 2006;95:62-6.
12. Agarwal T, Patel B, Rajan P, et al. Core biopsy versus FNAC for palpable breast cancers. Is image guidance 
necessary? Eur J Cancer. 2003;39:52-6.
13. Shannon J, Douglas-Jones AG, Dallimore NS. Conversion to core biopsy in preoperative diagnosis of breast 
lesions: is it justified by results? J Clin Pathol. 2001;54:762-5.
14. Saxe A, Phillips E, Orfanou P, et al. Role of sample adequacy in fine needle aspiration biopsy of palpable 
breast lesions. Am J Surg. 2001;182:369-71.
15. Shin HJ, Sneige N, Staerkel GA. Utility of punch biopsy for lesions that are hard to aspirate by conventional 
fine-needle aspiration. Cancer (Cancer Cytopathol). 1999;25:149-54.
38
Indeterminate FNA
16. Lamb J, Anderson TJ. Influence of cancer histology on the success of fine needle aspiration of the breast. J 
Clin Pathol. 1989; 42:733-5.
17. Florentine BD, Cobb CJ, Frankel K, et al. Core needle biopsy. A useful adjunct to fine-needle aspiration in 
select patients with palpable breast lesions. Cancer (Cancer Cytopathol). 1997; 81:33-9.
18. Masood S. Core needle biopsy versus fine needle aspiration biopsy: are there similar sampling and 
diagnostic issues? Clin Lab Med. 2005;25:679-88.
19. Boerner S, Sneige N. Specimen adequacy and false-negative diagnosis rate in fine-needle aspirates of 
palpable breast masses. Cancer (Cancer Cytopathol). 1998;25(84):344-8.
20. Westenend PJ, Sever AR, Beekman-De Volder HJ, et al. A comparison of aspiration cytology and core 
needle biopsy in the evaluation of breast lesions. Cancer (Cancer Cytopathol). 2001;93:146-50.
21. Barra Ade A, Gobbi H, de L Rezende CA, et al. A comparision of aspiration cytology and core needle 
biopsy according to tumor size of suspicious breast lesions. Diagn Cytopathol. 2008;36:26-31.
22. Smitt MC, Horst K. Association of clinical and pathologic variables with lumpectomy surgical margin status 
after preoperative diagnosis or excisional biopsy of invasive breast cancer. Ann Surg Oncol. 2007;14:1040-
4.
23. van Deurzen CH, Hobbelink MG, van Hillegersberg R, et al. Is there an indication for sentinel node biopsy 
in patients with ductal carcinoma in situ of the breast? A review. Eur J Cancer. 2007;43:993-1001.
24. Buijs-van der Woude T, Verkooijen HM, Pijnappel RM, et al. Cost comparison between stereotactic large- 
core-needle biopsy versus surgical excision biopsy in The Netherlands. Eur J Cancer. 2001;37:1736-45.
25. Dillon MF, McDermott EW, Hill AD, et al. Predictive value of breast lesions of ‘‘uncertain malignant 
potential’’ and ‘‘suspicious for malignancy’’ determined by needle core biopsy. Ann Surg Oncol. 
2007;14:704-11.
39

Chapter 4
The diagnostic value of nipple discharge cytology 
in 618 consecutive patients
B.W. Kooistra, C.A.P. Wauters, S. van de Ven, L.J.A. Strobbe
Eur J Surg Oncol. 2009 Jun;35(6):573-7
Chapter 4
ABSTRACT
Background
Preoperative stratification of patients presenting with nipple discharge (ND) according to 
malignancy risk has proven difficult. Nevertheless, cytological examination is considered to 
be a diagnostic aid. The aim of this study was to determine its complementary value in 
clinical decision-making in patients presenting with ND.
Methods
We retrospectively collected data on macroscopic ND colour, ND cytology, physical 
examination, mammography, ultrasound and fine-needle aspiration cytology results. On ND 
cytology, benign diagnoses were considered negative, whereas suspicious and 
malignant diagnoses were considered positive for malignancy.
Results
From 1992 to 2006, 618 patients had an ND smear, of those 163 patients had a biopsy. 
Sensitivity and specificity were 16.7% and 66.1%, respectively. These values were lower 
when ND was bloody than when ND was non-bloody ( p=0.66 and p<0.05 for sensitivity and 
specificity, respectively). When macroscopically defining bloody ND as positive and non- 
bloody ND as negative, macroscopic ND colour examination had a remarkably higher 
sensitivity (60.6 vs. 18.2%, p < 0.001) and only a slightly lower specificity (53.6 vs. 
65.0%, p=0.07) when compared to cytological ND examination. Only 1 malignant lesion was 
designated positive solely by ND cytology (unique sensitivity (95% CI), 2.8% (0.0-8.4%)) 
and 3 lesions were correctly classified as negative by ND cytology (unique specificity (95% 
CI), 1.6%, 0.0-3.7%)).
Conclusion
Nipple discharge cytology has little complementary diagnostic value. Therefore, its routine 
use for detection of ND-related breast pathology should be reconsidered carefully. Nipple 
discharge cytology may redirect patient management well in some cases, but it may confuse 
work-up in the majority.
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Nipple discharge (ND) is the third most frequent complaint of patients visiting a breast clinic, 
being the presenting symptom in 4-7% of cases.1-3 Additionally, it accounts for 6-7% of 
breast surgical indications, ranking only second to a lump.4,5 To the public the occurrence 
of ND has been ringing an alarm bell announcing breast cancer. However, preoperative risk 
stratification by a minimally invasive diagnostic work-up has proven difficult.3,6 In the past 
decades the concept of pathologic ND has been introduced for this purpose.
Yet, controversy remains concerning the criteria of pathologic ND. Several studies regard 
unilateral, single-duct, spontaneous and persistent discharge as pathologic 6-11 As others 
include expressible1,5,12,13 and bilateral ND 4,14 as well, reported malignancy rates in 
pathological discharges range from 6-29%.
In addition, it has been questioned whether discharge colour correlates to histological 
diagnosis. Some authors reported higher malignancy rates in bloody ND,6,13 whereas others 
found no association.8,11,14
Traditionally, pathologic ND is evaluated by cytological examination of fluid smears. 
Although there are additional diagnostic clues in a majority of cases,4,15 ND smears 
may detect malignancy reliably when other clues are absent. It is questionable however, how 
often this is the case.
The unique contribution of cytology to diagnosing pathologic ND has never been 
investigated. The present study aimed to retrospectively evaluate this by correlating 
cytological and histological diagnoses in cases of unequivocal positive or negative signs 
found by other diagnostic modalities. A further hypothesis was that solely 
examining macroscopic ND colour would at least be as accurate as the cytological 
examination of an ND smear.
MATERIALS AND METHODS 
Study population
We included all patients presenting with unilateral spontaneous and expressible ND from 
whom material for cytology was obtained. As spontaneous ND may be temporarily absent at 
clinical presentation, we also included expressible ND. The patients were seen in a regional 
teaching and a regional non-teaching hospital. Following exclusion of patients that were 
pregnant (n=9), lactating (n=3) or had bilateral discharge (n=98), a 618-patient series 
remained eligible for analysis. We did not include patients with bilateral ND since this does 
not usually raise clinical suspicion of focal breast pathology. We included only patients who 
had ND smears until August 1, 2006, allowing for a minimal follow-up of 2 years. We chose 
this time interval because more than 40% of ND-secreting breast cancers in our group was 
excised more than 1 year following the ND smear.
INTRODUCTION
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Data collection
We searched patient files for clinical and radiological findings. We extracted pathology data 
from the Dutch nationwide pathology data network and archive (PALGA).
We noted the macroscopic colour of the discharge. For purposes of comparing diagnostic 
accuracies, we considered bloody ND as suspect for malignancy. A positive 
physical examination was defined as either a palpable mass, nipple retraction or pagetoid 
nipple aspect. Mammographic criteria for malignancy included irregular microcalcifications 
or a spiculated or irregular mass, whereas well-demarcated masses, polycystic architectural 
disturbance and gross microcalcifications were considered benign lesions. Ultrasound 
malignancy criteria were echogenic lesion within a dilated duct or a mottled hypoechoic 
architectural disturbance. We considered duct dilatation without a mass as benign.
ND acquisition and interpretation
Surgeons obtained ND by gently pressing the areola. ND was directly smeared onto a 
specimen slide and either fixated in ethanol 95% and Papanicolaou-stained, or air-dried and 
Giemsa-stained.
Pathologists assigned each smear one of the National Cancer Institute-recommended 
diagnostic categories: benign, atypical, suspicious or malignant.16 A specimen was diagnosed 
'benign' if  no or few epithelial cells were present. Specimens diagnosed 'malignant' contained 
several dyscohesive clusters of anaplastic cells and, optionally, a necrotic background. For 
accuracy calculation, benign ND was considered negative for malignancy, while 
both suspicious and malignant ND were considered positive. Although not conclusive, 
suspicious cytology leads to further diagnostic evaluation, in fact bearing the same 
consequence as a malignant diagnosis.
Histology
We correlated smears to their later histological diagnosis if  established within 5 years 
following cytology. Ductal carcinoma in situ (DCIS) and invasive ductal and lobular 
carcinoma (IDC and ILC, respectively) were considered malignant. In spite of carrying 
increased risks of malignant degeneration,17-19 we designated atypical ductal hyperplasia 
(ADH) and papillomas as benign.
Twelve staff pathologists with 6-20 years of cytopathological experience examined both 
cytological and histological specimens. Clinical information or a prior cytological diagnosis 
was available to the pathologists.
Statistical analysis
We calculated sensitivity and specificity of ND cytology, as well as unique sensitivity and 
specificity. We defined unique sensitivity as the proportion of malignancies that was 
detected solely by cytology and unique specificity as the proportion of benign breast lesions 
that was designated malignant by examination, mammography and ultrasound, but benign by 
cytology.
We ran Chi-square and Fisher’s exact tests for comparing proportions, whereas 95% 
confidence intervals (95% CI) for proportions were calculated by the Cloppere Pearson 
method.20 We used SPSS 14.0 software (SPSS Inc., Chicago, IL) for calculations.
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RESULTS 
Patients’ characteristics and histology
From January 1, 1992 to August 1, 2006, 618 eligible ND smears were made. During this 
period approximately 24,000 new patients had visited the study centres.
In this group median patient age was 50 years (range, 20-86) and 614 patients were women. 
Of these, 163 had histological follow-up, which we further analysed. Histology comprised 
excision or mastectomy in 160 cases and core needle biopsy in 3 cases. Median time between 
cytology and histology was 50 days (range, 0-1627). Overall, solitary papilloma was the most 
frequent surgical finding (n=51). Malignancy was identified in 36 cases in this group, of 
which 19 tumours were DCIS, 2 were pT1a, 3 were pT1c, 7 were pT2, 3 were pT3 and 2 
were pT4b. Five tumours were grade 1, 12 were grade 2 and 19 were grade 3. No previous 
diagnoses of breast cancer had been established in these women.
Overall diagnostic accuracy
Measures of cytological diagnostic accuracy are noted in Table 1. ND smears detected 5 of 
36 malignancies and 84 of 127 benign lesions (Table 1). Malignant lesions 
showed somewhat higher rates of positive and atypical cytological diagnoses. Nevertheless, 
ND smear diagnosis did not significantly predict the histological nature of the ND- 
causing breast lesion (x2 = 5.0, p= 0.082).
Table 1 Smear diagnoses in malignant and benign breast lesions presenting with nipple discharge 
(n = 163).
Cytological diagnosis Histology
Benign Malignant
Benign 66.1 % 50.0 %
Atypical 27.6 % 33.3 %
Positive 6.3 % 16.7 %
ND colour
In smears with available ND colour and histology data (n=156), cytological analysis of 
bloody ND had similar sensitivity (Fisher’s exact p=0.66) and lower specificity (x2 = 7.2, 
p= 0.007) when compared to otherwise coloured ND (Table 2).
Table 2 Smear accuracy in cases of bloody and non-bloody discharge (n = 156).a
Bloody Non-bloody
Sensitivity 15.0 % 23.1 %
Specificity 52.6 % 75.8 % f
fp < 0.01 for smear specificy in bloody vs. non-bloody discharge. 
a For cases with available colour data only.
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Table 3 shows comparative sensitivities and specificities of macroscopic examination of ND 
colour alone and ND cytology in the same group as was analyzed in Table 2. The sensitivity 
of colour examination was higher than the sensitivity of cytological examination 
(x2 = 12.4, p < 0 .001). For specificity, no significant difference was found (x2 = 3.3, 
p = 0.069).
Table 3 Diagnostic accuracy of macroscopic discharge colour and cytology (n = 156).a
ND colourb Cytology
Sensitivity (95 % CI) 60.6 % (43.0-78.2 %) 18.2 % (4.3-32.1 %)*
Specificity (95 % CI) 53.6 % (44.7-62.6 %) 65.0 % (56.5-73.6 %)
tp = 0.001.
a For cases with available colour data only.
b When regarding red discharge as positive and non-red discharge as negative.
Complementary diagnostic value
In the histology group data on clinical examination were available for all 163 cases. 
Mammography, ultrasound and FNA were performed in 155, 106 and 10 cases, respectively. 
Sixty-one patients had a lump on clinical examination. No breast lesion was detected by 
physical examination and imaging in 50 cases. Of these patients, 8 (16%) turned out to have 
breast cancer. Of all malignant lesions, 8 were designated benign by each of these diagnostic 
modalities, if  performed (Table 4). Of these, 1 ND smear was still able to detect malignancy, 
thus carrying a unique sensitivity (95% CI) of 2.8% (0.0-8.4%). In addition, 4 smears were 
diagnosed as atypical, apparently necessitating histological biopsy in these cases. In 2 benign 
lesions the ND smear was the only negative diagnostic finding, indicating a unique specificity 
(95% CI) of 1.6% (0.0-3.7%). Yet, no mammography was performed in 1 of these cases.
DISCUSSION
The present series shows that ND smears had a very low complementary diagnostic value in 
both benign and malignant breast lesions that cause pathologic ND. Still, smears of ND are
performed in many centres because they may incidentally detect a carcinoma.9,11,14,21-23 The
rationale for this is that although cytology carries a low sensitivity, a positive finding is 
alarming all the same because of its acceptable specificity. Furthermore, the ease of 
obtaining ND and preparing a smear has led to its common use for cytological examination.
Potential advantages of ND cytology
The group where the potential advantage of cytology lies is small but interesting for it 
includes those patients with discharging lesions that lie too deep for detection by palpation or 
too well hidden in a dense breast for conventional imaging.2,24,25 Early cytological detection 
of breast cancers in this group may limit the extent of surgical and adjuvant therapy and 
improve prognosis. Nevertheless, relatively low malignancy rates are found in these patients 
in the present (16%) and other studies (0-13%),6,9,11,26,27 which partly explains the low 
unique sensitivity of cytology. Over a 14.5-year period, with an estimated total of 1450 breast
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Tabel 4 Diagnoses of nipple discharge smears in cases with concordant findings on physical examination, 
mammography, ultrasound and fine-needle aspiration.
Histology
Benign (n = 127) Malignant (n = 36)
All other m odalities3 positive 2 2
Negative cytology 2 2
A typical cytology 0 0
Positive cytology 0 0
All other m odalities3 negative 76 8
Negative cytology 48 25
Atypical cytology 25 3
Positive cytology 3 1
a Examination, mammography, ultrasound and fine-needle aspiration (if performed).
cancers being treated in the two study centres, only one patient with breast cancer received 
timely surgery solely due to positive cytology (2.8% of all breast malignancies presenting 
with ND). In other studies on ND cytology unique sensitivities of 5-7% were 
found.12,14 Cytology yielded the only negative finding in 2 out of 127 benign lesions, but 
these patients were still operated on. This indicates ignorance of negative cytology findings if
23,28,29they are not concordant with other diagnostic findings, as has been advocated before. , , 
Other diagnostic modalities
Actually, addressing ND with cytology may prove to be a futile adjunct to simple and more 
accurate diagnostic aids. Of patients with unilateral ND there is no clinical and radiological 
evidence of a breast lesion in only 25%. Reported sensitivities of physical examination, 
mammography and ultrasound range from 5-94%, 10-91% and 36-83%, respectively, 
whereas specificities of 50-93%, 38-99% and 12-68% have been reported,
respectively.1,4,5,7,8,10,11,24,26,30 Although mammography and ultrasound are independent
predictors of malignancy,11 cytology is not (Table 1), as emphasized by its low 
unique sensitivity and specificity (Table 4).
When disregarding other diagnostic modalities, cytology has an extremely low sensitivity 
(16.7%) and a low specificity (66.1%, Table 1). Reported sensitivities and specificities range 
from 11% to 82% and 81% to 100%, respectively4,5,7,9,11614,30,31 The fairly large 
differences with the present findings may in part be explained by the defined length of 
histological follow-up. Other studies may have adhered to a shorter maximum time interval 
of cytology to histology, thereby selecting those patients with advanced disease where 
cytological diagnosis may be easier. Determining if a late histological diagnosis explains the 
ND is hard and arbitrary. However, cancers can grow slowly over years and may still be 
identified after more than 10 years after clinical presentation.32 The high number of false- 
negative diagnoses may be the result of (1) only 1-5% of breast cancers producing ND 26,28 
and (2) cancer cells not always being present in ND.33 Further complicating the matter, the 
odds of malignancy cannot be reliably estimated on the basis of the degree of atypia, since 
discharged cells degenerate in the secreting duct.12 False-positive results are less frequent and 
may in part result from discharged atypical papilloma cells.14
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Macroscopic ND examination
In fact, even the examination of macroscopic ND colour alone may be a valuable alternative 
to ND cytology (Table 3). When bloody ND is considered positive for malignancy, ND 
colour examination has a remarkably higher sensitivity (60.6% vs. 18.2%, respectively) and 
only a slightly lower specificity (53.6% vs. 65.0%, respectively) when compared to ND 
cytology. In the presence of a test that could replace cytology for its specificity, such 
as physical examination, no single adjunctive benefit of cytology would remain.
Yet, in order to maximize their diagnostic yield, ND colour and cytology are used in 
conjunction with each other. Although most of the research on the two subjects has 
considered them separately, one study states that cytology is only useful in the diagnosis of 
bloody ND.22 Surprisingly, in the present study cytological examination of bloody ND has a 
lower specificity than otherwise coloured ND (Table 2). Cytology sensitivity was also lower 
for bloody ND, but this difference was not significant. This indicates a low relevance of 
cytology for clinically high-risk ND, mainly complicating diagnostic decision-making in 
these cases.
Study properties and implications
An acknowledged limitation of this study is its retrospective nature. ND characteristics, such 
as colour, uni- or bilaterality and spontaneity were obviously subjective. Moreover, these 
and other variables vary greatly in time in a substantial portion of ND patients. This may 
also clarify the many contradicting results in this field of research.
Regardless of its retrospectively established (unique) diagnostic accuracy, the role of ND 
cytology in clinical decision-making is questionable. Of course, clinicians should not rely on 
cytology alone. However, many authors still regard it as 'useful' in cancer detection. This 
notion is reflected by the current data as well. Suspect cytological diagnoses tend to be 
quickly followed by surgery, implying the clinician’s urge to obey cytological warnings. 
However, cytology does not predict surgical outcome (Table 1).
Conclusion
Nipple discharge smearing and its cytological examination have little complementary 
diagnostic value. Therefore, its routine use for detection of ND-related breast pathology 
should be reconsidered carefully. Nipple discharge cytology may usefully redirect patient 
management in some cases, but it may confuse work-up in the majority.
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ABSTRACT 
Background
To determine the value of cytology in the workup of male breast lesions, important for the 
management in a same-day breast clinic.
Methods
A total of 146 fine needle aspirations (FNAs) from the male breast were classified in the 
categories malignant, suspicious, atypical, benign and inadequate. Cytohistologic correlation 
was done.
Results
Histologic correlation was available in 85 cases. On FNA the 15 malignant cases were 
classified as malignant (n = 11), suspicious for malignancy (n = 2) or atypical (n = 2). Of the 
35 benign lesions on histology 3 cases were classified as atypia and 1 as suspicious for 
malignancy on FNA. In the inadequate FNAs (n = 45), the corresponding histologic 
specimens were benign, no carcinomas were diagnosed. The sensitivity and specificity of the 
FNA compared to the definite resection diagnosis were 100% and 90.2%, respectively. The 
results were comparable with the outcomes of the reviewed studies on male breast lesions in 
the recent literature.
Conclusion
Based on the nature of the benign breast lesions in man, a substantial number of inadequate 
FNAs were obtained. However, due to the good cytohistologic correlations in the group of 
malignant lesions, we can conclude that cytology remains an important diagnostic tool in the 
initial workup of male breast carcinomas.
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Fine needle aspiration (FNA) cytology has proven to be a quick, accurate and cost-effective 
method in the workup of all sorts of tumours from a variety of body sites.1 Despite the 
emerging role of the core needle biopsy (CNB), FNA continues to be a useful tool in the 
initial evaluation of breast masses.2 However, the core wash or core imprint technique is 
gaining in popularity, for these techniques generate a quick preliminary cytologic diagnosis, 
which is important for same-day patient counselling, while the histologic diagnosis follows 
within 24 hours.
Tumours of the male breast, especially carcinomas, are rare as compared to breast cancer in 
women. In the Netherlands, the incidence of breast carcinoma in men is 0.9 per 100,000 men 
as compared with 126.7 per 100,000 women (data from the Dutch Cancer Registry, 2006). 
The initial workup of a suspicious breast lesion in men is the same as is used for the female 
breast. In the case of asymmetry or a suspicious mass, FNA cytology is performed.
A limited number of studies have addressed the problems and pitfalls associated with male 
breast cytology.3-9 In this study we looked at the possible diagnostic problems that cytology 
can yield in male breast lesions and how to deal with them. In this regard, we focused on the 
proportion of nondiagnostic and atypical FNAs as both items preclude proper decision 
making. Does the moderate to severe atypia often seen in gynecomastia lead to false positive 
results in the FNA diagnosis?
The results of FNA male breast cytology over the past 16 years in our institute are used in 
addition to a critical review the literature from 2001.6,7,9
MATERIALS AND METHODS
All male breast FNAs, available CNBs and surgical specimens at our laboratory from January 
1992 to January 2008 were identified through the national pathology database of the 
Netherlands. The analyses of the current retrospective study were based on specimens from 
patients visiting a regional teaching hospital and a regional nonteaching hospital. In both 
hospitals breast patient care is managed according to national guidelines. Cytologic specimens 
were obtained by surgeons and radiologists. Either a 21- or a 23-gauge needle was used for 
aspiration. Before 1997 the aspirate was smeared onto a slide and instantly fixated in ethanol 
95% to a conventional smear. After 1997, most FNAs were liquid-based preparations (LBPs). 
In this cytospin technique the cells were rinsed from the needle and syringe into a vial and 
directly fixed in an ethanol 50%, polyethylene glycol 2% solution. A cytocentrifuge 
procedure was applied, creating a monolayer arrangement of all cells within a 12mm diameter 
area.8 Both conventional slides and LBP slides were Papanicolaou stained.
The slides were screened by cytotechnologists and examined by 10 staff cytopathologists with 
6-20 years of experience in cytopathology. Using simple and well-defined criteria, they 
classified each aspirate into one of the 5 diagnostic categories proposed by the 1996 National 
Cancer Institute-sponsored conference approach: malignant, suspicious for malignancy, 
atypical, benign and inadequate.10 We calculated the complete sensitivity as positive cases on 
FNA (atypia, suspicious for malignancy and malignant) divided by positive cases on
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histology (carcinoma or ductal carcinoma in situ), the absolute sensitivity as the only 
malignant cases on FNA divided by the malignant cases on the final histology and specificity 
as negative cases on FNA (benign) divided by nonmalignant cases on histology. Inadequate 
specimens were omitted from the accuracy calculation.
The sex was always known to the pathologist at the time of the cytopathologic examination. 
Further information regarding the clinical presentation of the breast lesion was mostly 
available to the pathologist. The cytologic diagnoses were correlated with the available 
histologic findings. The inadequate cases were reviewed independently by 2 pathologists and 
scored in 4 groups: no material, only blood, only some stromal elements and < 6 epithelial 
cell clusters. These outcomes were correlated with the available clinical information.
In order to put our figures in perspective, we compared our study with 3 recent published 
male studies. We performed some recalculations in the 3 studies for valid comparison and 
included only the cases with available histology; metastatic lesions were omitted.6,7,9
RESULTS
From January 1993 to January 2009, a period of 16 years, a total of 8,483 FNAs of the breast 
were examined. One hundred forty-seven FNAs (1.7%) were from 147 male breasts. They all 
underwent unilateral FNA cytology. The median age of the patients was 53 years (range, 15­
95). The median time interval between FNA and histology was 21 days.
Satisfactory aspirates were obtained in 83 of the 147 cases. These were categorized as benign 
in 78 cases, atypical in 9 cases, suspicious for malignancy in 3 cases and malignant in 11 
cases. Forty-five of the 146 cases had unsatisfactory aspirates, which were not useful for 
cytologic examination.
Histologic examinations on excisions and biopsy or mastectomy specimens were available in 
85 of the 147 FNA cases (Table 1).
Fifteen of the 16 histologically documented cases were primary male breast carcinomas, 
including 14 infiltrating ductal carcinomas and one apocrine carcinoma. One tumour was a 
metastatic neuroendocrine lung tumour. The clinical presentation of the primary breast 
carcinomas suggested in 11 cases a palpable tumour, suspicious for carcinoma, in 1 case a 
palpable tumour probably benign, 2 cases with a palpable tumour not otherwise specified and 
one case a lesion suspicious for a cyst. The corresponding FNA diagnosis was malignant in 11 
cases, suspicious for carcinoma in 2 cases and atypical in 2 cases. One FNA diagnosis 
suspicious for carcinoma showed on the slide only a few atypical cells; the other showed 
proliferating duct epithelium with atypia. In the 2 cases atypical on FNA, 1 tumour of the 
cutaneous appendages was suggested on cytology, and the other atypical case was the only 
apocrine carcinoma on histology.
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Table1 Correlation of 85 FNA cytology diagnoses with the corresponding histologic diagnoses
Histologic diagnosis
FNA diagnoses
Malignant Suspicious Atypical Benign
Unsatisfactory/
Inadequate
Primary breast carcinoma 11 2 2
Metastasis 1
Gynecomastia 1 3 25 15
Infection 8 3
Lipoma o f fatty tissue 2 3
Fibrosis 4
Others 2 3
Total 12 3 5 37 28
Of the 78 cases reported cytologically as benign, histology was available in 37. All 37 cases 
were benign lesions, with 25 reported as gynecomastia, 8 cases as infections, 2 cases as 
lipoma or fatty tissue, 1 case as syringomatous adenoma of the nipple and 1 case of normal 
tissue on histology.
The 29 cases of gynecomastia on histology had an adequate FNA. The clinical information 
with the FNA suggested in 4 cases a malignant tumour, in 3 cases a benign tumour, in 16 
cases gynecomastia and in 1 case a lipoma. In 5 cases no clinical information was available. 
The case suspicious for malignancy on FNA and gynecomastia in the final histologic 
diagnosis had no clinical data. The clinical information on the 3 cases atypical on FNA 
suggested in 2 cases gynecomastia, and in 1 case the clinician suspected a malignancy.
Of 45 cases diagnosed as unsatisfactory or inadequate on FNA, 28 had histologic follow-up. 
The 28 specimens revealed 15 gynecomastia cases, 3 infection cases, 3 lipoma cases or fatty 
tissue, 4 fibrotic tissue cases, 1 hemangioma, 1 benign cyst and 1 biopsy that was not 
representative. For the 17 cases without follow-up we checked the national pathology 
databank; no carcinomas were seen.
The inadequate specimens were reviewed. In 14 cases no cell material was seen, in 15 cases 
only blood, in 5 cases only some stromal elements and in 3 cases < 6 epithelial cell clusters. 
Two cases were not available in the archive. The clinical information suggested a malignancy 
in 7 cases, a benign tumor in 12 cases, in 11 cases there was no clinical judgment about the 
palpable lesion, a gynecomastia was suspected in 9 cases, an infection in 4 cases, a lipoma in 
1 case and a cyst in 1 case (Table 2).
The diagnosis of atypia was reported on FNA 9 times. Five cases had histologic follow-up. 
Three cases eventually proved to be gynecomastia. In 2 cases a diagnostic CNB revealed 
breast cancer, followed by a mastectomy.
The absolute sensitivity was 71.4%; the complete sensitivity was 100%. The specificity was 
90.2%.
Review of the Recent Literature
Westenend and Jobse9 included 153 FNAs of the male breast out of a group of 'more than 
10,000 FNAs' during a period of 15 years (approximately 1.5%). One hundred forty-one 
samples were from unilateral lesions. Of all male breast FNAs 9.8% were primary malignant
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breast tumours. In the unsatisfactory FNAs (18, 11.7%) no carcinoma or ductal carcinoma in
Table 2 The reviewed 45 inadequate FNAs: correlation between clinical information (vertical) and defined 
cytologic categories (horizontal) with the available histologic follow-up
Cytological score
No material Blood Stromal elements
<6 epithelial cell 
clusters No slides
No. Hist. No. Hist. No. Hist. No. Hist. No. Hist.
Clinical information
Malignant tumour 
(n=7)
3 1 gyn 2 1 gyn 1 
1 lipoma
1 infection 1 1 gyn -
Benign tumor 
(n=12)
3 2 gyn 5 1 gyn 2 
1 cyst 1 hg
1 gyn 2 
1 not repr.
1 gyn -
Tumour NOS
(n=11)
2 2 gyn 3 2 fibrosis 1 1 infection 3 1 gyn 2 1 lipoma
Gynaecomastia
(n=9)
4 2 gyn 5 1 gyn - 
1 lipoma
- -
Infection
(n=4)
2 1 gyn - 1 
1 infection
1 fibrosis 1 1 infection -
Cyst/lipoma
(n=2)
- - 2 -
Total 14 15 5 9 2
No., number of cases cytologic categories; Hist., histology; Tumour NOS, tumour not otherwise specified; 
Gyn, gynecomastia; hg, haemangioma; Not repr., not representative
situ was found. The amount of atypical or suspicious for malignancy cases on FNA with 
related histology was not mentioned; however, the sensitivity was 100% and the specificity 
89% when the inadequate FNAs were excluded (Table 3).
Siddiqui et al7 reported on 520 diagnostic aspirates from a palpable lump in a male breast out 
of a total group of 14,026 breast FNAs (male and female, 3.7%) in a period of 10 years. All 
aspirates of the male breast were from unilateral lesions. The FNAs revealed malignancy in 
32 cases. Fifteen cases were breast carcinomas; however, only 14 were primary breast 
carcinomas (ductal carcinoma not otherwise specified) with corresponding histology. In 170 
cases histology was available. Of all male FNAs 6.1% were malignancies; only 2.8% were 
primary male breast carcinomas. On FNA atypia or suspicious for malignancy was diagnosed 
in 61 cases. The corresponding histology was available in 57 cases and revealed 7 carcinomas 
and 2 ductal carcinoma in situ cases. Ninety-four (15.4%) cases were unsatisfactory on FNA; 
the corresponding tissue diagnosis, available in 21 cases, showed 1 ductal carcinoma in situ 
and 1 carcinoma. Considering malignant, suspicious for malignancy and atypia on FNA as 
positive, the calculated sensitivity was 95.3% and the specificity 100%.
Macintosh et al6 studied, with 2 groups of observers, the accuracy and reproducibility of FNA 
on the male breast; this was the third large study on male breast carcinomas since 2001 that 
we compared. They reported on 138 breast FNAs performed on 123 male patients. One third, 
46 FNAs (33.3%), were unsatisfactory. Histologic correlation was available for 23 
satisfactory FNAs. Eleven cases were primary breast carcinomas on histology. The 
corresponding FNAs were malignant in 7 cases and suspicious for malignancy in 4 cases. The
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12 benign cases showed on FNA unremarkable or proliferative characteristics in 11 cases and 
atypical in 1 case by 1 group of observers; the other group considered all corresponding FNAs 
unremarkable or proliferative. The sensitivity was 95.5% and the specificity 100%.
The sensitivity calculated in the 3 studies was only the complete sensitivity; the absolute 
sensitivity was not available.
DISCUSSION
In this study, 1.7% of all breast FNAs were from the male breast. In all large cytologic studies 
of breast lesions, FNA on the male breast constitutes 1.54-3% of the total cases.3-9 The 
majority of male breast lesions turned out to be benign. Although the incidence of male breast 
carcinomas is increasing, it still remains a very rare condition as compared to the incidence in 
females.3-9,11 In our study 10.2% of all male breast FNAs were primary malignant tumours; 
one lesion was metastatic. The complete sensitivity and the specificity of FNA as compared to 
the definitive resection diagnosis were 100% and 90.2%, respectively.
Table 3 Results of this study in comparison with the studies by Westenend and Jobse, Siddiqui et al and 
Macintosh et al
2002 2002 2008 2009 this
Result W estenend Siddiqui Macintosh study
No. o f male FNAs (% male FNAs o f all 153 (1,5%) 614 (4,3%) 138 (3,2%) 147 (1,7%)
breast FNAs)
No. o f cases with histologic follow-up 72 170 23 85
No. o f malignant cases (% primary breast 15 (9,8%) 26 (2,8%) 11 (7,9%) 15 (10,2% )*
carcinomas)
No. o f unsatisfactory cases o f all FNAs 18 (11,7%) 94 (15,4%) 46 (33,3%) 45 (30,6%)
No. o f unsatisfactory FNAs with histologic 10** 21** *** 28
follow-up
Sensitivity 100% 95,3% 95,5% 100%
Specificity 89% 100% 100% 90,2%
*The metastases were excluded from the calculations.
**In both studies inadequate FNAs revealed 2 carcinomas in follow-up. 
***The unsatisfactory or inadequate cases were not discussed in this study
Because the last review of the literature on male breast lesions dates from 2001, we compared 
our results with those of 3 large studies since 20026,7,9 (Table 2). In line with these studies we 
considered atypia, suspicious for malignancy and malignant as a positive result and benign as 
a negative result. In order to compare the data, it was necessary to draw 1 line although we 
were aware that the further workup of the breast lesion is different for atypia and suspicious 
for malignancy than for the FNA diagnosis malignant. After all, the latter result does not need 
a complementary CNB.
Our study and the study by Westenend and Jobse9 showed the highest percentage of primary 
breast carcinomas diagnosed on FNA cytology, 10.2% and 9.8%, respectively. Siddiqui et al7
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had a percentage of only 2.8. As shown in Table 2, the sensitivity ranged from 89.7% to 
100%. The specificity of 90.2% in our study was due to 4 false positive FNA diagnoses on 
gynecomastia.
Gynecomastia is the most common cause of masses in the male breast and is defined as the 
enlargement of the male breast due to proliferation of both glandular and stromal elements.12 
According to the literature and the cytologic textbooks, gynecomastia may present on FNA 
with dyshesive groups and sheets of ductular cells with moderate to severe nuclear atypia.3,8 
Because of these cytologic criteria, one should expect many cases of atypia on FNA. 
Westenend and Jobse9 mentioned < 1% atypia, and the other 2 studies did not report the 
frequency of atypia as a diagnostic group. In our study, atypia was diagnosed in 11 cases on 
FNA. Five cases had histologic follow-up. Two cases were carcinomas on histology, and 3 
were gynecomastia.
Our study showed 44 cases of gynecomastia. One case was diagnosed as suspicious for 
malignancy, and in 3 cases the diagnosis atypia was reported on FNA. Malignant was never 
the FNA diagnosis in cases of gynecomastia.
So, in contrast to what was expected, we can conclude that in practice the diagnosis 
gynecomastia did not give much of a challenge on FNA. However, gynecomastias render a 
substantial number of unsatisfactory or inadequate cases on FNA. As shown, 15 of the 44 
cases were inadequate (Table 2). In line with other authors who also had this high percentage 
of unsatisfactory cases, we think it is due to the nature of the lesion, gynecomastia, and not to 
the FNA technique itself.
All studies showed many unsatisfactory cases, ranging from 11.7% to 33.3%.6,7,9 In our study 
we had 45 (30.6%) unsatisfactory cases on FNA. However, in the clinical presentation a 
malignant lesion was suspected only 7 times. Twenty-eight cases had histologic followup, and 
no carcinomas were observed. The unsatisfactory cases in the studies by Westenend and 
Jobse9 and Siddiqui et al7 both had 2 carcinomas on histology. MacIntosh et al6 did not 
discuss unsatisfactory or inadequate samples.
or the last decade, CNB has been introduced and for several reasons is preferred in the 
workup of breast lesions. However, in order to obtain a quick preliminary diagnosis, essential 
for the management of the 1-day breast clinic, core wash or touch imprint cytology of the 
CNB can be done, for it can provide a diagnosis within half an hour. However, the 
interpretation of the slides obtained by the wash or imprint techniques are still based on the 
cytologic criteria of the FNA. In this respect, we can combine the benefits of both modalities 
in the future.
Conclusion
Despite not yielding a conclusive diagnosis in a substantial number of cases, the high 
sensitivity and specificity justifies primarily opting for cytology in the initial diagnostic 
workup of male breast lesions.
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ABSTRACT 
Background
Core wash or touch imprint cytology is often used to obtain a quick, preliminary diagnosis on 
a core needle biopsy (CNB) of breast lesions, essential for the management of the 1-day 
breast clinic. Contradictory results of both techniques in the literature led to this preclinical 
study investigating an alternative method of touch imprint and core wash cytology.
Methods
Thirty breast lesions were biopsied by a core needle in a laboratory setting. The CNBs were 
collected in RPMI fluid (Roswell Park Memorial Institute fluid). The touch imprint cytology 
was performed taking the biopsy out of the fluid and smearing it on a microscopic slide and 
May-Grunwald Giemsa stained. The core wash cytology was made by fixating the remaining 
cells in Fixcyt and prepared with a liquid-based preparation method and Papanicolaou stained. 
The cytologic findings were categorized into benign, atypical favoring benign, atypical, 
suspicious, and malignant and compared with the histologic CNB results.
Results
The CNBs showed 20 of 30 samples to be malignant, 2 to be phylloides tumours, 7 to be 
benign, and 1 to be unsatisfactory. Both techniques showed a sensitivity of 95% and 
specificity of 100%. Touch imprint yielded insufficient diagnoses (13.3%), compared with 
core wash (6.6%). Of the core wash cases, 86% showed a good quality versus 30% in touch 
imprint cytology.
Conclusion
This preclinical study on modified touch imprint and core wash techniques led to results that 
were comparable to or better than those in the literature. The core wash cytology is preferred 
to touch imprint because of the better morphology.
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Fine-needle aspiration (FNA) cytology is frequently used in the instant diagnosis of breast 
lesions. The histologic diagnosis, however, gains importance in the initial diagnostic workup. 
A core needle biopsy (CNB) is often preferred to cytology because it can provide more 
information about the tumour characteristics, precise type of carcinoma, and hormonal and 
other receptor status.
However, CNB diagnosis requires 24 hours of processing whereas cytology can allow 
diagnosis within 1 hour.1 A quick reliable preliminary diagnosis is very important for same- 
day patient counselling and expedites the planning of further surgical or neoadjuvant 
management. Immediate diagnosis of breast lesions is also useful for alleviating patient 
anxiety. Most patients prefer to receive their results on the same day as their tests.2-6 
Core wash in a saline solution or touch imprint cytology could be an answer to this problem. 
There are several studies about touch imprint cytology derived from CNBs in breast lesions. 
The sensitivity and specificity vary from 74%-100% and 83.7%-100%, respectively.1-4,7-9 The 
described procedures, however, result in a substantial proportion of unsatisfactory samples.
It was recently stated that core wash cytology was not useful at all for the immediate 
diagnosis of breast lesions by ultrasound-guided CNB.6 A sensitivity and specificity of 89% 
and 75%, respectively, was shown with a 42% unsatisfactory rate.
In trying to integrate a rapid preliminary diagnosis with CNB, both core wash and touch 
imprint techniques were modified. The modified core wash and touch imprint procedures 
were tested in an in vitro laboratory setting. The cytologic results were correlated to the CNB 
histology.
MATERIALS AND METHODS
In a laboratory setting, 30 lesions in 27 surgical resected breast specimens (lumps, 
mastectomies) were biopsied before fixation by 1 cytologic technician or 1 pathologist. Two 
to 3 CNBs per lesion were obtained in 18 in vivo palpable and 12 nonpalpable breast lesions 
with an 18-gauge needle (Bard Needle Monopty, eGeneral Medical Inc., Murray Hill, NJ) and 
biopsy gun. No ultrasound guidance or other imaging techniques were used.
Unique and in contrast to other preparation manuals, the biopsies were collected in 6 mL 
RPMI medium (Roswell Park Memorial Institute, Invitrogen, Breda, the Netherlands). To 
each 500 mL, 0.5 grams Natrium-azide (Sigma-Aldrich Chemie B.V., Zwijndrecht, the 
Netherlands) and 5 grams of bovine serum albumin were added. The biopsies stayed in this 
mixture for 5-10 minutes. The needle tip was rinsed in the medium.
The touch imprint cytology preparations included carefully taking the biopsy out of the 
medium and smearing it on a microscopic slide. The touch imprint slides were air dried and 
May-Grunwald Giemsa stained.
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Table1 Explanative terminology of core wash and touch imprint cytology diagnosis categories
Core W ash/Touch Imprint 
Diagnosis Positive/Negative Adequacy
Inadequate - Inadequate
Benign Negative -
Atypia favouring benign - -
Atypia - Adequate
Suspicious for carcinoma Positive -
M a lig n a n t - -
After this, the biopsy was fixated in formalin, paraffin embedded, and H&E stained.
The core wash cytology preparations included fixing the remaining cells in the medium for 10 
minutes in 2 mL Fixcyt (50% ethanol and 2% polyethylene glycol solution). According to the 
operator manuals, this mixture was centrifuged for 10 minutes at 688 rpm in a Hettich Rotina 
48S or Hettich Rotanta 46S centrifuge (Andreas Hettich GmbH & Co.KG, Tuttlingen, 
Germany). Supernatant was discarded. Depending on the estimated density of the sediment, 1 
or 2 drops of the ethanol 50% and polyethylene glycol 2% solution were added. The resultant 
mixture was dripped into a bucket that was clasped on a polysine slide (Menzel GmbH, 
Braunschweig, Germany). By centrifuging for 5 minutes at 688 rpm, the sediment was 
pressed onto the slide, creating a monolayer arrangement of all cells within a 12 mm diameter 
area.10 The liquid based preparation slides were Papanicolaou-stained.
To quantify the quality of the cells, we scored the morphology of the cells into 3 categories: 
poor, not optimal, and good morphology. In the case of poor morphology, no diagnosis could 
be made. In the case of suboptimal morphology, it was hard to make a diagnosis but possible. 
With the good morphology case, a diagnosis was easy to make.
The cellularity was also divided in 3 groups: poor (<6 epithelial cell clusters), moderate (6-10 
epithelial cell clusters), and rich (>10 epithelial cell clusters). The presence of more than 6 
epithelial cell clusters was required for adequate classification.
According to international guidelines for FNA cytology, the core wash and touch imprint 
cytological findings were categorized as follows: benign, atypical favouring benign, atypical, 
suspicious for carcinoma, malignant, or inadequate (Table 1). On CNB histologic diagnosis, 
we considered carcinoma, suspicious for carcinoma, and ductal carcinoma in situ (DCIS) as 
positive for carcinoma. 'Not representative' and 'no material' were put in the unsatisfactory 
category.
Two experienced observers read the CNB histology and the core wash and touch imprint 
slides in a blinded fashion. The results of the core wash and touch imprint cytology were 
correlated with the diagnosis of the CNB. Sensitivity was defined as the proportion of positive 
and suspicious core wash or touch imprint cytology cases in malignant lesions (which include 
DCIS, carcinoma, and suspicious for carcinoma) on CNB histology.
Specificity was defined as the number of negative core wash or touch imprint cytology cases 
divided by the number of positive and negative cytology specimens with subsequent benign 
histology on CNB. 'Not representative' and 'no material' were put in the unsatisfactory 
category and left out of the calculations.
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RESULTS
The CNBs were histologically diagnosed as carcinoma (n = 17), DCIS (n = 1), suspicious for 
carcinoma (n = 2), atypical stroma/phylloides tumour (n = 2), benign (n = 7), and not 
representative/normal breast tissue (n = 1). The benign category (n = 7) comprised 
fibroadenoma (FA; n = 1), FA/fibrotic breast tissue (n = 2), fibrotic breast tissue (n = 3), and 
sclerosing adenosis (n =1).
The core wash corresponding to the 20 malignant CNBs were cytologically diagnosed as 
malignant in 15 cases (75%), suspicious in 4 cases (20%), and atypia favouring benign in 1 
case (5%) (Table 2). The atypia case on core wash was suggestive of carcinoma on CNB.
Table 2 Correlation of diagnoses of core wash cytology and coordinating core needle biopsy histology
Core Needle Biopsy Histology
Cytologic
Diagnosis
Positive for 
carcinoma Phylloides Benign Unsatisfactory
Carcinoma 15 - - -
Suspicious 4 - - -
Atypia favouring 1 2 6 -
Unsatisfactory - - 1 1
Total 20 2 7 1
All atypical cases diagnosed in core wash were atypia favouring benign. The phylloides 
tumours were diagnosed as atypia on core wash with the remark of stromal atypia. The 
sclerosing adenosis case was diagnosed as atypia on core wash. The FA in the CNB showed 
atypia consistent with FA on core wash. In 2 cases, it was not possible to differentiate 
between FA and fibrotic breast tissue on CNB. The corresponding core wash revealed 1 
unsatisfactory and 1 atypia specimen. Fibrotic breast tissue on CNB, 3 cases, was once 
diagnosed as unsatisfactory and twice as atypical on core wash. The sensitivity was 95% and 
the specificity was 100%.
The touch imprint corresponding to the 20 histological diagnosed carcinomas comprised 15 
carcinomas (75%), 3 suspicious (15%), 1 atypia favouring benign (5%), and 1 unsatisfactory 
(5%) (Table 3). The phylloides tumours were also diagnosed as stromal atypia. The CNB 
diagnosis of sclerosing adenosis showed atypia on touch imprint. The FA on CNB revealed 
atypia on touch imprint, FA/sclerosing adenosis was in the touch imprint 2 times 
unsatisfactory, and fibrotic tissue was in touch imprint once unsatisfactory and twice atypia. 
Normal breast tissue on CNB showed atypia on touch imprint. The atypia seen in touch 
imprint was atypia favouring benign. The sensitivity was 95% and the specificity was 100%. 
Core wash and touch imprint showed almost the same results in cellularity. It was poor in 2 
core wash (7%) cases and in 3 touch imprint (10%) cases, moderate in 3 core wash (10%) 
cases and in 2 touch imprint (7%) cases. Twenty-five cases (83%) showed a rich cellularity in 
both core wash and touch imprint techniques.
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Table 3 Correlation of diagnoses of touch imprint cytology and coordinating core needle biopsy histology
Core Needle Biopsy Histology
Cytologic Positive for
Diagnosis carcinoma Phylloides Benign Unsatisfactory
Carcinoma 15 - - -
Suspicious 3 - - -
Atypia favouring 1 2 4 1
Unsatisfactory 1 - 3 -
Total 20 2 7 1
The morphology was poor in 2 core wash cases (7%) and in 4 touch imprint cases (13%).
Although not optimal, a diagnosis could be made in again 2 core wash cases (7%) and in 17
touch imprint cases (57%). The morphology was good in 26 core wash cases (86%) and in 9
touch imprint cases (30%) (Table 4).
Table 4 Quality morphology in core wash and touch imprint
Quality Core Wash Touch Imprint
Poor 2 4
Moderate 2 17
Good 26 9
Total 30 30
DISCUSSION
In the initial diagnostic workup, the CNB yields more essential information about the tumour. 
However, an evaluation of the tissue sample requires 24 hours of processing. A rapid 
diagnostic method to cytological analysis of the CNB can offer a diagnosis in 1 hour. Only for 
the price of a touch imprint or core wash derived from a CNB, the clinician will be informed 
about the nature of the breast lesion and he will be able to plan further treatment the same 
day.
By using a modified processing technique for obtaining cytology from CNB, sensitivity and 
specificity for both core wash and touch imprint were 95 and 100%, respectively. The 
unsatisfactory rate was 6.6% in the core wash and 13.3% in the touch imprint cytology. In 
contrast to the literature, the malignant tumours were never unsatisfactory in our study.5-7 
The diagnostics accuracies of touch imprint and core wash cytology are conflicting in the 
literature.
Some authors reported a sensitivity and specificity of 85% and 98%, respectively, in their 
clinical study with core wash cytology, using a 16-gauge core needle.5 They had an 
unsatisfactory rate of 7% and regarded the core wash technique as useful for immediate 
diagnosis.
Others reported a sensitivity of 89% and a specificity of 72% of core wash cytology.6 The 
unsatisfactory rate in this study was 42%. A quarter of these unsatisfactory core wash results
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had a malignant diagnosis on CNB. The procedure was slightly different and they used an 18- 
gauge core needle. The study was done in a clinical setting. They concluded that the core 
wash technique was not useful for quick cytological diagnosis on CNB. A sensitivity and 
specificity of 100% each was seen in a study using an 11-gauge core needle.2 
Our figures can compete with these studies. However, we are aware that about 67% of the 
lesions in our study were malignant. We even did not have to worry about patients’ 
discomfort. But, to resemble a clinical setting, we took only 2 or 3 CNBs from each breast 
lesion. The studies performed in the clinic had the advantage of ultrasound-guided CNBs. In 
our study, no ultrasound guiding or other imaging techniques were used. The nonpalpable 
lesions were biopsied randomly.
Touch imprint cytology of the CNB has a more widespread use than the core wash. Some 
authors use it for evaluation of the quality of the CNB only.8 Others use the technique to 
investigate the possibility of needle tract seeding.11 Still, touch imprint is mostly used for 
providing a preliminary diagnosis. The sensitivity ranged from 74%95%, whereas specificity 
ranged from 97%-100%.1-4,7,9
As in the literature, we also had problems in classifying the benign lesions in the cytology.1 
Possibly, this is caused by the characteristics of these lesions. In benign tumours the 
cohesiveness of the tissue and cells is much higher than in malignant lesions.7,11 In our study, 
the histological benign diagnosis on touch imprint or core wash cytology was noticed as 
benign or atypia favouring benign.
Our study showed slight differences between core wash and touch imprint in figures. The 
unsatisfactory rates were 6.6% and 13.3%, respectively. The core wash was unsatisfactory in 
one benign and one unsatisfactory diagnosis on CNB. Touch imprint was tree times 
unsatisfactory on benign histology and once on suspicious for carcinoma on CNB. However, 
we are aware that we biopsied a small number of lesions.
The better cytological results in both the core wash and the touch imprint cytology in our 
laboratory could probably be attributed to the fact the CNB is collected in RPMI medium. The 
RPMI medium is used for the culture of human normal and neoplastic leukocytes. It has 
demonstrated wide applicability for supporting growth in many types of cultured cells. 
Therefore, it is a good medium in which to preserve the loosened cells optimally. This feature 
is in contrast to saline, which causes swelling of the cells and often leads to bursting of the 
cells.5,11
The better morphology seen in core wash (Table 4) is probably because of the finding that the 
cell material is worked up in a standardized procedure that collects all cells in the fluid and 
that is not operator-dependent.10 The quality of the touch imprint cytology is highly dependent 
on the manual skills of the person performing the biopsy and making the touch imprint slides. 
Another known advantage of core wash cytology is the microscopic evaluation. The cells are 
pressed in a monolayer arrangement within a 12 mm diameter area, whereas the microscopic 
screenings area with touch imprint cytology is the whole slide.
All these arguments turned the scale, in our practice, in choosing the core wash procedure at 
expense of touch imprint.
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Conclusion
In conclusion, according to our findings the modified core wash procedure can provide a 
reliable preliminary indication of the CNB results. This information is valuable for same-day 
patient counselling and management planning.
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ABSTRACT
Background
A quick and reliable preliminary diagnosis is essential in the management of a same-day 
breast clinic. In a preclinical study we developed an alternative method of core wash cytology 
(CWC). This study is an evaluation of this new CWC method introduced into the clinical 
setting.
Methods
From April 2008 to April 2009, biopsies were taken from lesions in the breast. CWC was 
obtained from core needle biopsy (CNB) with a modified technique and classified into the 
categories: malignant, suspicious for malignancy, atypical, benign and inadequate. CWC and 
CNB diagnoses were correlated with the histopathology of subsequently obtained resection 
specimens. The sensitivity and specificity were calculated.
Results
CWC was obtained from 226 breast lesions. In 167 of these cases subsequent resection of the 
lesion was performed revealing 149 carcinomas and 18 benign lesions. Of the 149 malignant 
cases, 136 were considered as either malignant or suspicious for malignancy by CWC, 7 as 
atypical, 4 as benign and 2 as inadequate. None of the 18 benign lesions were classified as 
suspicious or malignant on CWC. Eight out of 149 resected carcinomas were not recognized 
as malignant by histological analysis of the CNB, while 7 of these cases the CWC was 
considered malignant. The sensitivity and specificity were 97% and 100%, respectively.
Conclusion
In the vast majority of patients the modified CWC technique can provide a quick and reliable 
diagnosis of malignant breast lesions. Furthermore, combining CWC with CNB histology can 
improve adequate, preoperative recognition of the malignant character of breast lesions.
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The core needle biopsy (CNB) is increasingly being used as a first-line diagnostic modality in 
the diagnostic work-up of palpable and non-palpable breast lesions. Indeed, histological 
examination of such biopsies generally provides very important and detailed information 
about tumour characteristics, including subtype of carcinoma, hormonal status and other 
molecular features.
However, a same-day breast clinic requires a quick and reliable diagnosis for same-day 
patient counselling and optimal planning of further surgical or neo-adjuvant management. In 
most laboratories, a CNB diagnosis takes 12-24 h of processing. Core wash cytology (CWC) 
or touch imprint cytology (TIC) could be a solution for this problem because by cytological 
analysis a diagnosis can often be rendered within 1 h. Unfortunately, the results described in 
the literature with such cytological diagnostic approaches are variable. In studies on CWC the 
sensitivity and specificity varied from 85% to 89% and 72% to 98%, respectively, while the 
inadequate rate varied from 7% to 42%.1,2 Studies on TIC showed variable results as well.3-10 
We developed a modified CWC technique in which the collecting fluid is optimized and the 
processing is standardised. This technique was first tested in a laboratory setting and yielded 
very promising results, especially in malignant lesions.11 We then introduced the CWC 
approach into the clinical setting.
In this manuscript we present the results obtained in the first year after the introduction of the 
modified core wash technique.
MATERIALS AND METHODS 
Patient and tissues samples
From April 2008 to April 2009, CNBs were taken from palpable and non-palpable lesions in 
the female breast in our teaching hospital. According to the Breast Imaging Reporting and 
Data System (BI-RADS), developed by the American College of Radiology, biopsies were 
taken by the radiologist. Two to 3 CNBs per lesion were obtained by radiologists, using an 
18-gauge needle (Bard Peripheral Vascular, Inc., Tempe, Arizona USA) and biopsy gun under 
ultrasound guidance.
CWC technique
The biopsies were collected in 6 ml RPMI® medium (Roswell Park Memorial Institute, 
Invitrogen, Breda, The Netherlands). To each 500 ml RPMI 0.5 g Natrium-azide and 5 g 
Bovine Serum Albumin (SigmaeAldrich Chemie BV, Zwijndrecht, The Netherlands) were 
added. The biopsies were kept in the medium for 5-10 min, and additionally the needle tip 
was rinsed in the medium. Subsequently, the needle biopsies were removed from the medium 
by a cytological technician, fixed in formalin, paraffin embedded and haematoxylin and eosin 
stained (Fig. 1).
The CWC was performed by fixing the remaining cells in the medium for 10 min in 2 ml 
Fixcyt® (50% ethanol/ polyethylene glycol 2% solution). According to the operator’s 
manuals, this mixture was centrifuged for 10 min at 688 rpm in a Hettich Rotina 48S®or
INTRODUCTION
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Hettich Rotanta 46S8 centrifuge (Andreas Hettich GmbH & Co. KG, Tuttlingen, Germany). 
Next, the supernatant was discarded" and dependent on the estimated density o f the sediment, 
1 or 2 drops o f the Fixcyt8 solution was added. The resultant mixture was collected in a 
container and then put on a poly-L-lysine slide (Menzel GmbH, Braunschweig, Germany). By 
centrifuging for 5 min at 688 rpm, the sediment was pressed onto the slide, creating a 
monolayer arrangement o f all cells within a 12 mm diameter area.12'13 The liquid based 
preparation slides were Papanicolaoustained (Fig. 1). The preparation and the screening of the 
CWC slides were done by a cytotechnologist and supervised by a cytopathologist (total group 
in our centre consisting of 6 cytotechnologists and 8 pathologists with ample experience in 
cytopathology).
The clinician was informed about the CWC diagnosis within 1 h after puncture and about the 
histological diagnosis on CNB material early in the following morning.
Figure 1 Core wash cytology (CWC) procedure. After collecting the needle biopsy specimens in preservation fluid 
(a), the tissue fragments are gently rinsed in a syringe (b); subsequently, the tissue fragments are removed, the 
remaining fluid is centrifuged, and its cytological content deposited on a glass slide and stained for microscopical 
examination (c); the needle biopsy specimens are routinely processed for histological analysis (d); examples of 
the microscopy in a CWC sample (e) and of the accompanying needle biopsy specimen are depicted in resp. (e) 
and (f) (case of ductal breast cancer; original magnification in (e) x200, in (f) x200).
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Classification
The cytological criteria for CWC are exactly the same as those used for fine needle aspiration 
(FNA). The presence of more than 6 epithelial cell clusters was required for adequate 
classification.
According to international guidelines for FNA cytology, the CWC findings were categorized 
as benign, atypical, suspicious for malignancy, malignant or inadequate. Based on our 
preclinical study, on CNB, we considered carcinoma, suspicious for carcinoma and ductal 
carcinoma in situ (DCIS) as 'positive for carcinoma'.11 Not representative and no material 
were put in the inadequate category.
The results of the CWC were correlated with the histopathology of the CNB and, when 
available, subsequent resection specimens. The CWC test was considered as 'conclusive' 
when the diagnosis on CWC was malignant, suspicious for malignancy or benign. Sensitivity 
was defined as the proportion of malignant, suspicious for malignancy CWC cases divided by 
malignant (DCIS, suspicious for carcinoma and carcinoma) cases on the final resection 
specimen. Specificity was defined as the number of benign CWC cases divided by non- 
malignant cases on histology of the final resection specimen.
If the CWC diagnosis was malignant or suspicious for malignancy, the patients were planned 
for further surgical or neo-adjuvant management.
RESULTS
Patients and pathological findings
In a one year period (April 2008 - April 2009), CWC was obtained from the CNB of 226 
breast lesions. The age of the patients ranged from 21 to 92 years (median 57,5 years). In 167 
of these cases subsequent resection of the lesion was performed in the follow-up.
Table 1 Core wash cytology (CWC) diagnoses and core needle biopsy CNB histological diagnosis (in italics) in 
relation to the final histological diagnoses of malignant lesions in resection specimens.
Final malignant diagnoses
Malignant/suspicious 
for malignancy Atypia Benign Inadequate
Ductal carc. n = 111 105/107 4/0 1/1 1/3
Lobular carc. n = 24 18/24 3/0 2 /0 1/0
DCIS n = 7 6/3 0/0 0/0 0/0
O ther malignant lesions n = 7 7/7 0/0 0/0 0/0
Total n = 149 136/141 7/0 4/1 2/7
Malignant cases
The resection specimens revealed 149 carcinomas (ductal n = 111, lobular n = 24, DCIS n = 7 
(one grade 2 and 6 grade 3), mucinous n = 4, tubular n = 1, medullary n = 1, papillary n = 1). 
Of the 149 malignant cases, by CWC 136 cases were classified as either malignant (n = 110) 
or suspicious for malignancy (n = 26), 7 as atypical, 4 as benign and 2 as unsatisfactory 
(Table 1). Of the 111 cases of ductal carcinoma in the final specimen histology the CWC was
77
Chapter 7
'positive' in 105 cases (malignant n = 92; suspicious for malignancy n = 13), atypical in 4 
cases, benign in one case, and inadequate in one case. In 4 of these 111 cases the CWC 
diagnosis was malignant and the CNB diagnosis was inadequate (n = 3) or benign (n = 1). In 
the group of 24 lobular carcinomas CWC was 'positive' in 18 cases (malignant n =1 1 ;  
suspicious for malignancy n = 7), atypical in 3 cases, benign in 2 cases, and one case was 
non-diagnostic due to inadequate cytological material. In this lobular carcinoma group the 
histological CNB diagnosis was malignant in all cases.
In the group of 7 cases with DCIS, the final histology revealed one case with ductal 
carcinoma in situ grade 2, which was suspicious for malignancy on CWC and inadequate on 
CNB. Of the 6 DCIS grade 3 cases, one case revealed a benign diagnosis on CWC with 
insufficient diagnostic tissue on CNB. Two of three malignant cases on CNB were also 
malignant on CWC, one was suspicious for malignancy on CWC. However, two cases 
revealed the diagnosis suspicious for malignancy on CWC but the CNB was inadequate 
histological material and did not allow for a diagnosis on CNB.
The 7 mucinous, medullary, tubular and papillary carcinomas were all 'positive' on CWC 
(malignant n = 5, suspicious for malignancy n = 2) and CNB.
For confirmation of the CWC diagnosis in one of the 4 ductal carcinoma cases another 
(second) CNB was taken and in all DCIS cases.
Table 2 Results core wash cytology (CWC) diagnosis and core needle biopsy (CNB) (in italics) relation to the 
final benign diagnoses in resection specimens.
Final benign diagnoses
Malignant/suspicious 
for malignancy Atypia Benign Inadequate
Adenosis n = 4 0/0 2/0 0/4 2/0
Fibrous tumours n = 9 0/0 4 /1 4 /7 1/1
Intracystic papilloma n = 1 0/0 1/0 0/1 0/0
Others n = 4 0/0 0/0 4 /4 0/0
Total n = 18 0/0 7/1 8/16 3/1
Benign cases
Eighteen resected breast lesions were benign including 4 cases of adenosis, 9 benign fibrous 
tumours, one intracystic papilloma, one case of mastitis, 2 of fat necrosis, and one of 
mammary duct ectasia (Table 2). On CWC, none of these benign lesions were classified as 
suspicious for malignancy or malignant, 8 lesions were classified as benign, 7 as atypical, and
3 as inadequate.
The group of 9 fibrous tumours consisted of 6 fibroadenomas which were diagnosed as benign 
in 3 cases, and as atypical in 3 other cases on CWC. Two of the fibrous tumours were 
phyllodes tumours on final histological analysis, one case was diagnosed benign in both CWC 
and CNB histology and in the other case a diagnosis of atypia was given in both techniques. 
The ninth fibrous tumour was a desmoid fibromatosis which was diagnosed benign on CNB 
and was inadequate on CWC.
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The intracystic papilloma was diagnosed benign on CNB, however showed atypia on CWC. 
The cases with fat necrosis, mastitis and duct ectasia in the final specimen histology were 
benign in both the CWC and CNB histology.
The CWC test was considered as 'conclusive' (malignant, suspicious for malignancy or 
benign) in 88% of the cases. The sensitivity and specificity of the CWC diagnosis compared 
to the definite resection diagnosis was 97% (95% confidence interval: 93%-99%) and 100% 
(95% confidence interval: 59%-100%), respectively. The percentage of CWC examinations 
resulting in the diagnosis inadequate was 4.0%.
Cases without immediate biopsy or resection
In 59 cases no subsequent resection was performed. (Table 3) In 26 cases the CNB was 
malignant and in 33 cases benign. Of these 26 malignant cases, by CWC 24 cases were 
classified as either malignant (n = 21) or suspicious for malignancy (n = 3), and in 2 cases 
atypia was suggested on CWC.
Table 3 Results of core wash cytology (CWC) and core needle biopsy (CNB) of the 59 cases with only 'archival' 
follow-up confirmation of the diagnosis
CWC CNB
Final
diagnosis
Malignant/
suspicious Atypia Benign Inadequate Malignant Atypia Benign Inadequate
Malignant 
(adjuvant 
therapie) 
n = 15
15/0 0 0 0 15 0 0 0
Malignant 
(elderly) 
n = 10
6/3 1 0 0 10 0 0 0
Lymphoma 
n = 1
0/0 1 0 0 1 0 0 0
Benign 
n = 33
0/0 7 23 3 0 0 30 3
Total 
n = 59
21/3 9 23 3 26 0 30 3
Fifteen of these patients with malignant tumours without subsequent resection of the breast 
lesion underwent neo-adjuvant chemotherapy (mean age 45.6 years), 10 cases received 
hormonal therapy (mean age 83.6 years in this subgroup), and one patient had a diffuse large 
B-cell Non Hodgkin lymphoma (which was diagnosed as atypia on CWC) and received 
chemotherapy.
In none of the 33 cases with a benign CNB diagnosis a CWC diagnosis malignant or 
suspicious for malignancy was rendered. In these 33 cases, follow-up for pathological 
diagnosis by the Dutch Network and National Database for Pathology (PALGA), at least 6 
months after the CNB still did not reveal malignancy, supporting the benign nature of the 
breast lesion in these 33 patients.
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DISCUSSION 
Management breast clinic
For optimal organization of a same-day breast clinic a quick and reliable pathological 
diagnosis is warranted. A histological diagnosis in 1 h, at all times of the day, would be the 
best but is until today not available. Touch imprint cytology (TIC) or core wash cytology 
(CWC) could be a solution in a same-day breast clinic, but variable results were described for 
both techniques in the literature. A recent study on TIC revealed a sensitivity and specificity 
of 97.7% and 94.2%, respectively.10 Interestingly, in that study the inadequate cases (5%) 
were also excluded from the calculations, but in contrast to our study the cytological 
diagnosis atypia was included in the benign group. Our study shows that in case of the 
cytological diagnosis atypia further examination is needed to rule out malignancy.
Modified CWC technique
In a preclinical study we obtained very promising results with a modified CWC technique 
generating highly informative cytological material from CNBs.11 Therefore, we introduced 
this modified technique in the clinical setting. Both in the preclinical and clinical study, the 
specificity of a 'conclusive' CWC diagnosis was 100%. The sensitivity for this diagnosis was 
in this clinical study 97% and in the preclinical study 95%, respectively. The percentage of 
cases with a CWC diagnosis inadequate was comparable in the clinical and preclinical study 
(4.0% vs. 6.6%). As we stated in the preclinical study, it is important to note that the quality 
of the results on CWC are for a major part determined by factors such as the experience of the 
pathologists, the nature and the quality of the collecting medium, the standardised handling of 
the material by the technicians, and the cytospin monolayer preparation.3,11,13
Literature CWC
The recent CWC study of Uematsu et al. on 458 consecutive patients with breast lesions 
showed a sensitivity and specificity of 89 and 72%, respectively, while 42.2% of the samples 
were considered as inadequate.2 Also in that study inadequate samples were more often 
obtained from benign breast lesions which is probably due to the nature of these lesions. One 
older study describes similar diagnostic results: 7% inadequate samples on CWC and a 
sensitivity and specificity of 85 and 98%, respectively.1 Of note, Lankford et al. used a larger 
(16-gauge) core needle, while the 18-gauge needle we used may be more comfortable for the 
patient
Findings from this study
Our present clinical study confirms the observations of our preclinical study.11 In the 
malignant group, seven cases were classified as atypical on CWC (4 of 111 ductal and 3 of 24 
lobular carcinoma cases). In these cases the biopsies were generally very short and/or 
fragmented, and a smaller volume of biopsy material may very well result in a lower number 
of cells available for cytological diagnosis. Also, the percentage of the diagnosis atypia was 
significantly higher in the group of lobular carcinomas than in ductal carcinoma cases. This 
might be explained by the fact that lobular carcinoma cells often show only discrete nuclear 
atypia and can also mimic lymphocytes in cytological specimens. Cells of lobular carcinomas
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may therefore be more difficult to recognize as malignant cells, especially when few cells are 
available for cytological examination.
The 4 cases that were (also retrospectively) classified as benign on CWC and as malignant on 
CNB all had relatively few cells available for cytological examination but did meet the 
requirements for adequate material.
Extra diagnostic modality
Interestingly, in 8 cases with a final diagnosis of malignancy in the resection specimen, the 
histological examination of the CNB did not reveal malignancy. Of these, 4 ductal carcinoma
Figure 2 Diagram showing how in the present study the core wash cytology (CWC) diagnosis (because of its 
high sensitivity and specificity) could be used for same-day counselling and management decisions in the vast 
majority (88%) of the patients. CNB: core needle biopsy.
cases yielded inadequate material for diagnosis on CNB (n = 3) or a benign diagnosis (n = 1) 
on CNB. All these 4 cases were malignant on CWC. Additionally, 4 out of the 7 DCIS cases 
revealed inadequate material after tissue processing for a CNB histological diagnosis (only a
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minimal amount of tissue fragments could be recovered from the RPMI fluid), while in 3 of 
these 4 cases the CWC diagnosis was malignant.
A potential drawback of introducing CWC is that already small and vulnerable tissue 
specimens become even less suitable for subsequent histological analysis. However, 
disintegration of vulnerable tissue can already occur during transportation of the material to 
the pathology laboratory and during preparation for histological analysis anyway. 
Interestingly, in one of our cases material of two CNBs was submitted for pathological 
analysis, but one of these specimens was fragmented and lost for further histological analysis, 
while the other histologically only contained benign breast tissue. In this case the CNB 
diagnosis was 'benign', but the CWC diagnosis was 'malignant', probably because tumour 
cells were shed from the fragmented biopsy specimen into the liquid that was used for CWC 
analysis. As stated before, it is uncertain if such fragments would have yielded a proper 
diagnosis if  they were used for only histological analysis. In a substantial part of these cases,
7 out of 8 cases, a CWC diagnosis was rendered which allowed further management of the 
patients.
Five out of these 7 cases underwent a second CNB for confirmation of the CWC diagnosis. 
Benign lesions
This present study included 51 benign lesions (18 proven by histology on resection specimens 
and 33 cases with clinical but without histological follow-up). None of the benign cases in our 
study, however, had the diagnosis suspicious for malignancy or malignant on CWC, while in 
9 cases the diagnosis was atypia on CWC.
Patients planning
In our breast clinic we have the agreement to plan patients with a diagnosis malignant and 
suspicious for malignancy on CWC. Based on the results obtained in this study and the local 
agreement we created a flow chart illustrating the role of the CWC diagnosis in the 
management of patients in a sameday breast clinic (Fig. 2). The high sensitivity and 
specificity of a 'conclusive' (malignant/suspicious for malignancy and benign) diagnosis on 
CWC allows for rapid further planning of the vast majority of patients.
Conclusion
We conclude that, combining CNB with CWC analysis for the initial diagnostic work-up of 
breast lesions has some clear advantages: 1. The modified CWC technique can provide a 
quick and reliable diagnosis of (especially malignant) breast lesions, which is valuable for 
same-day patient counselling and management planning; 2. Combining CWC with CNB 
findings can lead to an increase in the number of adequate preoperative diagnoses of 
malignancy in breast lesions.
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ABSTRACT 
Background
To elucidate the contribution of cerebrospinal fluid (CSF) cytology to the management in 
breast cancer patients who present with neurological symptoms suspected for central nervous 
system (CNS) metastases.
Methods
From 1989-2009 eighty one patients with breast cancer underwent CSF cytological 
examination. Relevant tumour characteristics, clinical presentation and radiological findings 
were scored. The CSF cytological diagnosis was classified according to the 1996 NCI- 
sponsored conference approach as malignant, suspicious for malignancy, atypical, benign or 
inadequate.
Results
In 20 years, 145 CSF cytological examinations were performed. Relatively frequent 
neurological symptoms leading to CSF examination were headache (n = 25), nausea and 
vomiting (n=19), sensory disturbances (n=16), and cranial nerve dysfunction (n=16), of these 
headache and nausea/vomiting were most frequently associated with malignant cells in CSF 
(CSF+) (in 48% and 53% of the cases, respectively). All 4 patients with the combination of 
headache and confusion/alteration of mentality had CSF+. In 10 patients without radiological 
evidence for CNS metastasis CSF+ was found. In our series, the value of repeated CSF 
analysis was very limited, and CSF+ was strongly correlated with short survival.
Conclusion
A substantial number of patients with neurological symptoms but without radiological 
abnormalities can have CSF+. In our series the additional value of repeated cytological 
examination of CSF was very limited. Our study underscores that CSF cytology is a valuable 
tool for unequivocal diagnosis of metastatic spread of breast cancer to the CNS, and CSF+ is a 
strong predictor for poor survival.
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Breast cancer is (after lung cancer) the second most common source of central nervous system 
(CNS) metastases. Such metastases may present as intraparenchymal, leptomeningeal or dural 
lesions and as a combination of these. The reported incidence of CNS metastases of breast 
cancer is 3% to 15%.1-8 However, because of underdiagnosis and inaccurate reporting, the real 
incidence of metastatic breast cancer spread to the CNS is likely to be much higher, and an 
increase in reported incidence can be expected by improving diagnostic tools. Additionally, 
more effective treatment of primary breast cancer and of systemic (non-CNS) metastases of 
breast cancer will result in an increase in number of patients that survive long enough to 
present with CNS metastases.1-4, 8-11 Metastasis can reach the CNS via the haematogenous 
route and by direct infiltration from contiguous tumour deposits (e.g. bone metastases) or 
along the perineural or perivascular spaces. The interval between the diagnosis of primary 
breast cancer and the manifestation of CNS metastasis including leptomeningeal 
carcinomatosis (LC; synonym: meningitis carcinomatosa) varies significantly and is related to 
tumour characteristics such as tumour type and grade.11-14 Only very rarely CNS metastasis is 
the first manifestation of breast cancer.1, 15, 16
The neurological signs and symptoms of CNS metastases are widely variable and generally 
caused by increased intracranial pressure or neurological dysfunction due to local effect of the 
tumour. The neuroradiological findings are very divergent as well. With MRI- and CT-scan 
mass lesions or density differences can be detected in the brain parenchyma and the spinal 
cord. Leptomeningeal enhancement can be local or diffuse and can include nodules and 
enlargement or enhanced cranial nerves. In a substantial number of patients diffuse, 'non- 
tumefactive' leptomeningeal tumour growth occurs, this form is known as LC and can be very 
difficult to identify by radiological investigations.
Meanwhile, proof of metastatic disease in/around the CNS is important for rational 
therapeutic decision making (e.g. systemic and/or intrathecal chemotherapy, radiotherapy, 
wait and see policy). Cytology of cerebrospinal fluid (CSF) obtained by a lumbar puncture is 
generally considered as a quick, relatively easy, minimally invasive and inexpensive method 
to prove the presence or absence of metastatic spread to the CNS, and the diagnostic yield 
may be increased by analysis of repeated samples.2, 17 Recent studies on the diagnostic yield 
of CSF cytology in breast cancer patients are however sparse, and older studies were often 
based on post mortem investigations and/or data collected in patients with a wide spectrum of 
different tumors.18-20
In order to assess the value of a CSF cytological diagnosis in breast cancer patients presenting 
with neurological signs and symptoms suspected for metastatic spread to the CNS we 
conducted a retrospective study in which we compared the results of this cytological analysis 
with the clinical, neuroradiological, and survival data of these patients.
INTRODUCTION
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MATERIALS AND METHODS 
Patient population
In a period of 20 years (October 1989-October 2009), 1,106 CSF samples were cytologically 
analyzed in our department. Of these, 145 samples were obtained from 81 patients known 
with breast cancer. The patients of this retrospective study were identified through the Dutch 
nationwide histopathology and cytopathology data network and archive (PALGA).21 The 
patients were all female, the age at time of the CSF examination ranged from 33 to 85 years 
(mean 58.2 years). At time of the CSF analysis 80 patients were known with a breast 
carcinoma, while in one patient LC was the first presentation of a lobular breast carcinoma. In 
our series only 6 patients subsequently received chemotherapy and 2 of these patients 
received also radiotherapy on the brain. This group of patients was not separated in the 
calculations of survival.
Study design
145 CSF samples of the 81 patients with breast cancer were examined. The samples were 
obtained with a lumbar puncture by the radiologist or neurologist, using a 21-gauge needle 
(Bard Peripheral Vascular, Inc., Tempe, Arizona USA). All samples were received fresh, 
processed in the same laboratory and prepared by cytospin preparation technique. The slides 
were May Grunwald Giemsa and Papanicolaou stained. In a few cases (n=8) subsequent 
immunocytochemical analysis was performed, the results of this latter analysis are not 
included in this study.
According to international guidelines for fine needle aspiration (FNA) cytology, the CSF 
findings were classified in the categories proposed by the 1996 NCI-sponsored conference 
approach: malignant, suspicious for malignancy, atypical, benign and inadequate (the latter in 
this study esp. representing cases with ample admixture of blood). In case of more than one 
CSF examination, the 'most malignant' result (malignant > suspicious > atypical > benign) 
was used for the calculations. In this paper, malignant cells in CSF is abbreviated as CSF+ and 
benign CSF as CSF- . The slides were not reviewed.
Vital status and date of death were collected until March 18th 2010 and were obtained from 
the medical records. The overall (all-cause) survival was calculated from the day of the CSF 
examination until date of death or end of the follow up (March 18th 2010), whichever came 
first. The follow up period was at least 180 days long. The quality of life was not analyzed. 
Details of clinical signs and symptoms were retrieved from the clinical reports. The results of 
the computerized tomography (CT) scans and (contrast-enhanced) magnetic resonance 
imaging (MRI) scans of the CNS were retrieved from the radiological files. Metastases on 
radiology is abbreviated as Radiol+, no metastases on radiology as Radiol-. Metastases in the 
spine and/or skull may lead to neurological signs and symptoms, therefore breast cancer 
patients presenting with CNS symptoms due to such osseous metastases are included in the 
present study as well. The CSF cytological diagnoses were compared with the clinical, 
radiological, histopathological and survival data.
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Statistical analysis
Survival analysis was performed using the Kaplan-Meier method with the log rank test to test 
survival differences between CSF cytology diagnosis and radiology diagnosis groups. Values 
of p<.05 were considered significant. The statistical software package SPSS 15.0 (SPSS Inc., 
Chicago, Illinois) was used for analysis.
RESULTS
Neurological signs and symptoms
In the clinical records of 73 patients, 15 different neurological signs or symptoms were 
described that elicited further radiologic and pathologic evaluation. In 8 of the 81 patients the 
exact nature of the neurological signs or symptoms could not be retrieved. Many patients 
showed two (n=20) or more (n=25) signs or symptoms simultaneously. For this study a
Figure 1 Neurological signs and symptoms (in decreasing number) of the 81 patients related to the results of the 
CSF cytological examination
Inadequate 
■ Benign
maximum of three was scored per patient. The most frequently recorded symptoms were 
headache (n=25), nausea/vomiting (n=19), sensory disturbances (n=16), and cranial nerve III, 
IV, V VI and/or VII dysfunction (n=16) (Fig. 1). CSF+ was found in respectively 48%, 53%, 
13% and 13% of the patients with these symptoms. In 62% of the 13 patients presenting with 
the combination of headache and nausea/vomiting and in all 4 patients with the combination 
of headache and confusion/alteration of mentality malignant cells were found in the CSF.
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CSF cytology and survival
In Figure 2, CSF outcome is presented for each type of breast cancer. Malignant cells in CSF 
were relatively frequently found in patients with ductal carcinoma grade 3 (n=17,4%) and in 
lobular carcinoma (n=5,38%). In the remaining tumour categories only one out of 25 patients 
showed malignant cells in the CSF (n=1,4%).
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Figure 2 Tumour type primary breast 
carcinoma (ductal carcinoma grade I, II and III; 
lobular carcinoma, and other carcinomas 
(mucinous, apocrine, tubular, combined 
tubular/lobular, metaplastic carcinoma and 
ductal carcinoma in situ grade II)) related to 
cytological diagnosis of the CSF.
The patients included in this study underwent one (n=54), 2 (n=16), 3 (n=6), 4 (n=1), 6 (n=1),
8 (n=1), 10 (n=1) or 13 (n=1) CSF examinations. In one patient with repeated CSF analysis, 
the diagnosis changed from suspicious for malignancy into malignant, in another patient the 
diagnosis changed from benign to atypical. Multiple (> 6) CSF cytological examinations were 
performed in patients to monitor the effect of chemo- and/or radiotherapy.
The survival functions for patients with CSF+ or CSF- are shown in figure 3. The follow up 
varied from 3 to 4530 days and was at least 180 days in patients still alive in March 2010. In 
the group of 23 patients with the CSF+ all patients died within 11-240 days (median 45 days). 
Of the 44 patients with CSF-, 31 died within 3-3450 days (median survival of CSF- patients 
360 days, log rank test p<0.001). Eleven of these 31 patients with CSF- died within 6 months,
4 of these 11 patients showed LC and/or mass lesion, 2 osseous metastases in skull and/or 
spine on radiology, while 5 patients showed no radiological abnormalities (n=3) or had no 
radiology (n=2). However, 6 of these 11 patients suffered from systemic metastases and 7 had 
hypercalcaemia suggesting osseous metastases. Thirteen of the 44 CSF- patients were still 
alive at the end of the study, follow up ranging from 180-4530 days.
The one patient with the CSF cytological diagnosis suspicious for carcinoma died 1080 days 
after CSF diagnosis, while the 3 patients with a CSF diagnosis atypical were still alive at the 
end of the study, the follow up ranging from 420-860 days. Seven of the 10 patients with a 
CSF cytological diagnosis 'inadequate' died in 14 to 1442 days (mean 311 days), the 
remaining three patients were still alive 1080 to 1578 days after CSF examination.
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Figure 3 Association between the CFS results and survival of total 67 patients. (Kaplan Meier Curves) Median 
survival: 45 days (CSF+) and 360 days (CSF').
CSF+, malignant cells in CSF; CSF', no malignant cells in CSF.
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CSF cytology and survival after treatment
Of the 6 patients who received chemotherapy (in 2 patients combined with radiotherapy on 
the brain) five were CSF+ and one CSF-. The outcomes of this small group are incorporated in 
the overall calculations. However, the survival in this group of 6 patients ranged from 41-240 
days (mean 122 days) after CSF examination. The CSF- patient in this group had osseous 
metastases in the skull and died 60 days after CSF examination.
Radiologic findings and survival
Of the 81 patients, 31 had contrast enhanced CT scan (esp. in the first decade of the study 
period from which patients were retrieved) and 50 contrast enhanced MRI scan (esp. in the 
second half of the study period). Twelve of these patients had both CT and MRI examination 
of the CNS at the time of presentation with neurological signs and/or symptoms.
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Figure 4 The results of the CT- and MRI scan related with the results of the CSF examinations of the 81 patients. 
Mets, metastases; not clear, mass lesion or leptomeningeal metastases; HC, hydrocephalus; LM, leptomeningeal.
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CT-scan suggested: no metastasis (n=22/31), LC (n=2/31), intracerebral mass (n=5/31), 
hydrocephalus (n=1/31) and in one case it was hard to differentiate between a mass lesion or 
LC. MRI-scan revealed: no metastasis (23/50), spinal (n=4/50) and/or cranial LC (n=4/50), 
intracerebral mass lesions (n=5/50) and in 4 cases it was impossible to differentiate between a 
mass lesion or LC. One out of four cranial LC cases had also an intracrerebral mass lesion. 
Osseous metastases were also detected on MRI (n=10/50), in one of these patients combined 
with LC. The CSF outcomes are related with the radiologic findings in Figure 4. Of note, in 6 
patients with CT scans and 4 patients with MRI scans no explanation was found for the 
neurological symptoms, however CSF examination in these patients did reveal tumour cells. 
Twelve of the 81 patients underwent both contrast enhanced CT- and MRI scan. In 9 patients 
the findings on CT and MRI were consistent. In 3 patients MRI investigation revealed 
metastasis and CT imaging did not. Additionally, in 4 patients, radiological examination 
revealed disc herniation (n=2) and cerebral infarction (n=2) instead of malignancy as a cause 
of the neurological symptoms.
Twelve of the 81 patients had no CT or MRI scan. In this group of 12 patients CSF was 
malignant, atypical and benign in 3, 1 and 8 patients, respectively. Nine of these patients died 
within 6 to 660 days.
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Figure 5 Association between the CT and/or MRI findings. (Kaplan Meier Curves) Median survival: 180 days 
(Radiol+) and 330 days (Radiol-).
CSF+, malignant cells in CSF; CSF-, no malignant cells in CSF. Radiol+, malignancy on radiology; Radiol-, no 
malignancy on radiology.
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We also examined the association between radiologic findings and survival. (figure 5) 
Metastases on CT and/or MRI were seen in 32 patients. Of them, 27 patients died in 9-1590 
days (median survival 180 days). Five patients were still alive with a follow up of 180-860 
days (1 with an intradural metastasis in the spine, 3 with LC and/or a mass lesion in the brain,
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Figure 6 Association between the combined CT/ MRI and CSF results and survival. (Kaplan Meier Curves) 
Median survival: 90 days (CSF+ , Radiol+), 41 days (CSF+ , Radiol-), 240 days (CSF- , Radiol+) and 1530 days 
(CSF- , Radiol-).
CSF+, malignant cells in CSF; CSF-, no malignant cells in CSF. Radiol+, malignancy on radiology; Radiol -, no 
malignancy on radiology.
Survival (days)
Num ber o f patients at risk
Days 0 1000 2000 3000 4000 5000
CSF- / Radiol- 18 8 4 3 1 0
CSF- / Radiol+ 18 1 0 0 0 0
CSF+ / Radiol- 9 0 0 0 0 0
CSF+ / Radiol+ 11 0 0 0 0 0
and 1 with an osseous metastasis in the skull). Radiol" was seen in 36 patients, with a follow
up of 3-4530 days, median survival 330 days. Twenty five of them died within 5-3450 days. 
Of the 17 patients that died relatively rapidly (within 6 months), 9 had CSF+, 5 had systemic 
disease and 12 patients had osseous metastases in the body (hypercalcaemia). Survival was 
better in Radiol" than in Radiol+ patients, although not statistically significant (log rank test
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Finally, we compared the combined results of CSF cytology and radiological findings with 
survival. (Fig 6) The median survival for patients with CSF+/Radiol+, CSF+/Radiol-, 
CSF-/Radiol+ and CSFTRadiol- was 90, 41, 240 and 1530 days, respectively. Retrospective 
analysis of the cases causing the steep part of the CSFTRadiol- curve showed that these 
patients suffered from systemic disease and/or hypercalcaemia. The flat part of the 
CSF7Radiol+ slope was caused by 20 patients with a survival of up to 1590 days. Six of these 
Radiol+ patients had skull and/or spine metastases rather than metastases in the intradural 
compartment.
DISCUSSION
In the present study we evaluated the contribution of cytological examination of the CSF 
using Papanicolaou and May Grunwald Giemsa stains in breast cancer patients presenting 
with neurological signs and symptoms in a period of two decades. One of the first reports on 
carcinoma cells in the CSF is from Dufour in 1904.22 Interestingly, many of the frequently 
cited results in literature on this topic are relatively old and/or based on autopsy reports. 3 6 23 
Due to improved therapeutic efficacy in patients with systemic metastases of (breast) cancer, 
the frequency of CNS metastasis has substantially increased.1 The reported incidence of CNS 
metastases of breast tumours in clinical series is 3-15%, thereby it represents the most 
frequently detected CNS metastasis in large studies.2, 8 15 11, 14 It is likely that the real 
incidence is even much higher as autopsy studies reported incidences ranging from 18% to 
30%.9, 18-20 Metastatic carcinoma cells reach the leptomeninges and subarachnoidal space by 
haematogenous spread or by direct extension from solid tumour lesions and subsequent 
dissemination in the CSF compartment. Examination of the CSF is theoretically a good 
modality for confirmation of the existence of such metastatic spread to the CNS.
CNS metastasis can generate multiple neurological signs and/or symptoms.1-3, 7 24 The 4 most 
frequent symptoms in our series were headache, nausea/vomiting, sensory disturbance 
(extremities and cauda equina region), and cranial nerve dysfunction. Of note, no single 
neurological sign or symptom, nor a particular combination of these symptoms was a strong 
predictor of finding malignant cells in the CSF (except for the combination of headache and 
confusion/altered mentality, but this latter group consisted of only 4 patients). Furthermore, of 
course neurological symptoms in breast cancer patients can also very well be due to non­
neoplastic disease. This is illustrated by the fact that in our series disc herniation and cerebral 
infarction was found in 4 patients as an explanation for their neurological symptoms and, 
indirectly, by the fact that a substantial number of the patients in our series (especially those 
with CSF- and Radiol) showed a much longer survival than would be expected when CNS 
metastasis was indeed present.
Ductal and lobular carcinoma are the most frequent types of breast carcinomas. As expected, 
this was also true in our study (91% of total number of breast carcinomas). Moreover, of all 
diagnoses 'malignant'on CSF cytology 74% were metastatic ductal carcinomas grade III. LC 
is usually seen in patients with systemic disease, or can be seen after a disease-free period and 
occasionally, in the absence of a primary tumour.1, 11, 15, 16 In our study, in one patient the
p=0.06).
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initial manifestation of a lobular breast carcinoma was LC with malignant cells in the CSF. 
Twenty seven patients (33%) underwent more than one CSF examination. While it is stated in 
the literature that multiple punctures increase the diagnostic accuracy of CSF cytology, in our 
series repeated punctures only led to a slight difference in diagnosis in two cases (suspicious 
for carcinoma became malignant in one case and benign became to be atypical in another).1-3, 
23, 25 In this series repeated cytological analyses thus did not really help to improve the CSF 
cytology diagnosis.
In the literature the mean survival of untreated metastases to the central nervous system of 
breast carcinomas is given as 4 to 6 weeks, the mean overall survival of patients treated for 
LC is given as 6 to 7.5 months, while survival can be up to 16 months or incidentally even 
more than 30 months if surgical excision of a solitary metastasis is performed. 4 10, 11, 14, 26, 27 
Our study showed a significant difference in survival between patients with a benign (CSF-) 
versus malignant (CSF+) diagnosis on CSF examination. The 23 CSF+ patients showed a 
median survival of 45 days, while 44 CSF- patients had a median survival of 360 days. Of this 
latter group, 11 patients died within 6 months, of these 4 patients showed on radiology LC 
and/or mass lesions and 2 patients revealed osseous metastases.
Comparison of the CT- and MRI scan results with survival indicates that, if  no metastases are 
seen the survival is better than when metastastic disease can be demonstrated and vice versa, 
although this was not statistically significant. Patients with metastases on radiology had a 
median survival of 180 days, while patients with CSF+ showed a median survival of 45 days. 
CSF+ thus predicts a somewhat worse survival for the patient than metastases on radiology. 
The discrepancy between this difference on survival between radiological and CSF findings 
may partly be explained by the fact that intraosseous but extradural metastatic lesions on 
radiology may have less effect on survival than 'real' CNS metastasis with spread of tumour 
cells into the CSF.
It is important to realize that the group of patients presented in this study represents a 
selection of the whole group of breast carcinoma patients with CNS metastases as not in every 
breast cancer patient that develops neurological symptoms CSF examination will be 
performed. Moreover, in the nineties of the previous century CSF examination was in our 
centre generally the first diagnostic modality applied, followed by CT-scan examination, 
while the current national guidelines in the Netherlands for patients suspected for CNS 
metastasis of (breast) cancer advise to first perform a MRI scan, and only if  no metastases are 
seen on radiology CSF examination is advocated. This change means that it would be less 
easy nowadays to collect a fair number of patients that had both metastatic disease on 
radiological and CSF cytological examination. Also, it is generally accepted that MRI scans 
are superior to CT scans when it comes to radiological detection of (metastatic) diseases of 
the CNS.28, 29
These changes in indications to perform different diagnostic tests and improved techniques 
will thus have an influence on figures as presented here, and further improvements in 
diagnostic techniques are almost continuously made. For instance, recently a nomogram was 
published that can be used to calculate the risk on CNS metastasis for patients with breast 
cancer. Based on such a nomogram high-risk patients can be identified and selected for e.g. 
upfront neo-adjuvant therapy in order to prevent the occurrence of CNS metastases.11 Still, as 
soon as breast cancer patients present with neurological problems additional investigations are
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warranted. Of course, radiological detection is now much better than 20 years ago, and 
detection of metastatic disease in/around the CNS was probably more recently further 
improved with the introduction of 3Tesla MR scanners.28, 30 Also, morphological analysis of 
the CSF is now often supplemented by immunocytochemical staining, and in addition 
molecular analysis is increasingly used in diagnostic pathology to improve the detection of 
malignancy in the CSF.31-36
Although our present, retrospective study thus has its limitations, the results do allow us to 
draw some meaningful conclusions: 1.CSF cytology leads to an unequivocal diagnosis of 
metastatic spread to the CNS in a substantial number of breast cancer patients; 2. Malignant 
cells in the CSF is a strong predictor for poor survival of these patients; 3. Combination of 
both diagnostic modalities (radiology and CSF examination) can have extra value; 4. The 
additional value of repeated cytological examination of CSF was in our series very limited; 5. 
Malignant CSF cytology was relatively frequently found in grade III ductal carcinoma 
patients and in lobular carcinoma patients; 6. Single neurological signs or symptoms nor 
combinations there-of are a good predictor for the chance of finding malignant cells in the 
CSF.
Conclusion
We conclude that cytological examination of the CSF in breast cancer patients presenting 
with neurological symptoms is still a valuable, inexpensive, minimally invasive tool for 
unequival demonstration of CNS metastasis of breast cancer. Esp. when malignant cells are 
demonstrated in the CSF, this tool provides important prognostic information that will aid in 
therapeutic decision making. However, in order to further improve evidence-based clinical 
practice in this area, larger studies are needed to assess the exact value of the improved 
radiological and pathological diagnostic approaches in patients suspected for CNS metastases 
of breast cancer.
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Chapter 9
The studies presented in this thesis focus on the value of cytological examination in the 
diagnostic work-up and management of patients with breast lesions, especially for a 'same- 
day breast clinic'. In such a clinic on the day of the first outpatient visit the patient is informed 
of the nature of the breast lesion (benign or malignant) and further treatment is planned. In 
addition, in this thesis the value of cytological examination of the cerebrospinal fluid in breast 
cancer patients presenting with neurological symptoms was studied.
In chapter 2 we reported our diagnostic experience with a monolayer preparation (MP) 
technique of breast FNA, employing the Hettich centrifuge. The FNA diagnoses were 
classified into one of the 5 diagnostic categories as proposed by the 1996 National Cancer 
Institute-sponsored conference approach: malignant (C5), suspicious for malignancy (C4), 
atypical (C3), benign (C2) and inadequate (C1). The reference standard was the histological 
follow-up. A conclusive FNA diagnosis was defined as C2 (in lesions benign in follow-up) 
and C5 (in lesions malignant on histology). In this retrospective study aspirates processed by 
conventional smears (CS) (1992-1996) were compared with aspirates processed by MP 
(1999-2003). We demonstrated that MP-prepared FNA significantly more often resulted in a 
conclusive diagnosis compared with CS-prepared FNA.
In chapter 3 repeat FNA and CNB were compared with regard to their ability to provide a 
clinically useful diagnosis after indeterminate primary breast FNA. After correction for 
patient age, mammographic presentation, clinical findings, tumour size, freehand or image 
guided aspiration, the study reveals significantly better results with the CNB than with the 
repeat FNA.
The value of cytological examination of nipple discharge (ND) in clinical decision-making is 
reported in chapter 4. We found a very low additional diagnostic value compared to clinical 
evaluation and subsequent histological examination in both benign and malignant breast 
lesions that cause pathologic ND. The sensitivity of ND cytology is low, but a positive 
finding has acceptable specificity and is therefore alarming. Interestingly, ND colour (esp. 
'bloody' vs. 'milky') examination had a higher sensitivity and only a slightly lower specificity 
when compared with ND cytology. The specificity of the cytological examination of bloody 
ND was significantly lower than in otherwise coloured ND. Our results indicate that 
cytological examination of ND has limited value for clinical decision making If a carcinoma 
is not evident in ND cytology, the clinician must be aware of the low relevance and therefore 
possibly misleading results of the ND.
In chapter 5 the value of FNA in the work-up of male breast lesions was determined over a 
period of 15 years. A substantial number of inadequate FNAs were obtained in this patient 
group which can be explained by the fact that gynaecomastia is the predominant nature of 
male breast lesions. However, due to the good cytologic correlations in the group of 
malignant lesions, cytology still can be considered as an important diagnostic tool in the 
work-up of clinically suspect male breast lesions. The results of our study were comparable to 
those in studies reported in the recent literature.
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In chapter 6 a preclinical study is described investigating a modified method of TI and CW 
cytology in patients with breast cancer. (ref) Fresh breast specimen, obtained after surgery, 
were biopsied by a core needle in a laboratory setting. With the modified technique TI and 
CW slides were made and categorized as inadequate (C1), benign (C2), atypical (C3), 
suspicious for malignancy (C4) and malignant (C5) and compared with the histologic CNB 
results (ref). The study showed only a slight difference between CW and TI cytology. 
However, because of the better morphology and the advantages of the monolayer technique 
that was applied in preparation of CW specimen, the CW cytology technique was preferred 
and subsequently introduced into the clinical setting.
The first clinical data on CW cytological diagnosis in this context are presented in chapter 7. 
CW cytology and the CNB histological diagnoses obtained from 226 breast lesions were 
correlated with the histopathology of subsequently obtained resection specimens. CW 
cytology resulted in good sensitivity and specificity compared to the histological resection 
diagnosis. Thus, the introduced modified CW cytology technique can provide a reliable 
preliminary indication of the likely CNB diagnosis and thereby a valuable tool suitably for 
same-day patient counselling and planning of further management.
In order to evaluate the value of cytological examination of the CSF in patients known with 
breast cancer that developed neurological signs and/or symptoms we designed a retrospective 
study. (chapter 8). We revealed that in a substantial number of patients with neurological 
symptoms but without radiological abnormalities, malignant cells can be found in the CSF. In 
contradiction with the literature the additional value of repeated cytological examination of 
CSF was very limited. The study underscored that CSF cytology is a valuable tool for 
unequivocal diagnosis of metastatic spread of breast cancer to the CNS. Also, the detection of 
malignant cells in the CSF proved to be a strong predictor for poor survival.
We are well aware of the controversy concerning the role of cytological examination in the 
management of breast abnormalities in general and non palpable breast lesion in particular. 
Based on the studies described in this thesis we conclude that cytological examination 
provides a rapid and reliable diagnosis in many patients and is therefore still a valuable aid in 
the diagnostic work-up of patients with breast lesions, esp. in a 'same-day breast clinic' in 
which ultra-rapid processing of biopsies for histological analysis is not (always) available. 
Other advantages of cytological analysis are that it is relatively inexpensive and technically 
easy to perform. However, for optimal preparation and evaluation of cytological specimens of 
breast lesions skilled personnel is crucial, and the diagnosis made on cytological specimens is 
usually less specific than diagnoses based on biopsy material (e.g. 'malignant' or 'carcinoma' 
on cytology vs. type of cancer and malignancy grade on histological analysis). Furthermore, 
using only the cytological approach leaves little material for additional immunocytochemical 
and/or molecular investigations. An important finding reported in this thesis is that rapid 
cytological analysis can be combined with histological examination of core needle biopsy 
material of a breast lesion without compromising the quality of the histological diagnosis, 
thereby significantly facilitating patient management in a 'same-day breast clinic'.
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We conclude that cytological examination is still a very valuable tool in the diagnostic work­
up and management of patients with breast lesions/breast cancer, and that it is important to 
maintain the high level of diagnostic skills in this field.
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De studies in dit proefschrift richten zich op de waarde van cytologisch onderzoek in de 
preoperatieve diagnostiek en het plannen van het verdere onderzoek en de behandeling van 
patiënten met borstafwijkingen, vooral belangrijk voor een 'zelfde-dag-borstkliniek' ('same- 
day breast clinic'). In een dergelijk centrum wordt op de dag van het eerste poliklinische 
bezoek de patiënt geïnformeerd over de aard van de borstlaesie (goedaardig of kwaadaardig) 
alsmede het verdere vervolgonderzoek en behandeling gepland. Tevens is in het kader van dit 
proefschrift de waarde van cytologisch onderzoek van de hersenvloeistof (liquor) onderzocht 
bij patiënten bekend met borstkanker die zich presenteren met neurologische klachten.
In hoofdstuk 2 rapporteren we onze diagnostische ervaring met de cytologische 'dunnelaag' 
techniek van dunne naald puncties (Fine Needle Aspiration: FNA) van borstafwijkingen, 
gebruik makend van de Hettich centrifuge. De FNA diagnosen worden ingedeeld in een van 
de 5 diagnostische categorieën, zoals beschreven in de 'Consensus statement on FNA of the 
breast' geformuleerd en geaccordeerd tijdens de in 1996 door het National Cancer Institute 
gesponsorde conferentie: maligne/kwaadaardig (C5), verdacht voor maligniteit (C4), atypie 
(C3), benigne/goedaardig (C2) en onvoldoende diagnostische cellen/materiaal (C1). De 
referentie-standaard was de diagnose op het weefsel (resectie preparaat) dat in de 
vervolgbehandeling door de chirurg werd weggenomen (de histologische follow-up). Een 
conclusieve FNA diagnose werd gedefinieerd als C2 (histologische follow-up goedaardig) en 
C5 (histologische follow-up maligne). In deze retrospectieve studie werden de puncties 
verwerkt met de 'dunnelaag' techniek (1999-2003) vergeleken met de puncties verwerkt tot 
conventionele uitstrijkjes (1992-1996). Uit de studie bleek dat de met 'dunnelaag' techniek 
verwerkte puncties significant vaker resulteerden in een conclusieve diagnose dan de puncties 
die verwerkt waren tot conventionele uitstrijken.
In hoofdstuk 3 worden de resultaten van de herhaalde cytologische punctie vergeleken met 
het holle naald weefsel biopt (Core Needle Biopsy: CNB) welke werden afgenomen nadat de 
eerste punctie uit een borstafwijking een 'niet-sluitende' (niet informatieve) diagnose had 
opgeleverd. Na correctie voor leeftijd van de patiënt, het mammografische beeld, klinische 
bevindingen, tumorgrootte, en het al dan niet echogeleid puncteren, blijkt dat er significant 
betere resultaten worden behaald met de CNB dan met het herhalen van de FNA.
Over de waarde van cytologisch onderzoek van tepelvocht in de klinische besluitvorming 
wordt gerapporteerd in hoofdstuk 4. We vonden een zeer lage aanvullende diagnostische 
waarde van het cytologisch onderzoek in vergelijking met de klinische evaluatie en het 
daaropvolgende weefsel (histologisch) onderzoek in zowel goedaardige als kwaadaardige 
laesies van borst die pathologisch tepelvocht veroorzaakten. De gevoeligheid (sensitiviteit) 
van de cytologische beoordeling van tepelvocht is laag, maar het vinden van een maligniteit 
heeft een aanvaardbare specificiteit en is daarom alarmerend. Bijzonder was de bevinding dat 
de beoordeling van de kleur van tepelvocht (vooral 'bloedig' versus 'melkachtig') een hogere 
sensitiviteit en slechts een iets lagere specificiteit had in vergelijking met de cytologische 
beoordeling van het tepelvocht. De specificiteit van het cytologisch onderzoek van bloedig
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tepelvocht was beduidend lager ten opzichte van anders gekleurd tepelvocht. Onze resultaten 
geven aan dat cytologisch onderzoek van tepelvocht beperkte waarde heeft voor de klinische 
besluitvorming. Indien bij cytologisch onderzoek niet een aperte maligniteit in het tepelvocht 
wordt aangetroffen moet de arts zich bewust zijn van de lage sensitiviteit en dus mogelijk 
misleidende informatie de cytologische beoordeling van het tepelvocht kan opleveren.
In hoofdstuk 5 wordt de waarde van de FNA in de diagnostiek van de borstafwijkingen bij de 
man beschreven in een retrospectieve studie over een periode van 15 jaar. Een aanzienlijk 
aantal 'niet-sluitende' diagnosen op de FNA werd afgegeven in deze groep patiënten, hetgeen 
verklaard kan worden door het feit dat het veelal een gynaecomastie betrof. Dit is cytologisch, 
gezien de aard van de laesie, lastig te diagnostiseren. Echter, vanwege de goede cytologische 
correlaties in de groep van maligne laesies kan de FNA nog steeds worden beschouwd als een 
belangrijk diagnostisch hulpmiddel in de diagnostiek van klinisch verdachte laesies in de 
borst van de man. De resultaten van onze studie waren vergelijkbaar met de gerapporteerde 
resultaten van studies uit de recente literatuur.
In hoofdstuk 6 worden in een preklinische studie twee gemodificeerde cytologische 
technieken beschreven waarbij celmateriaal van patiënten met borstkanker verkregen wordt 
van een dikke naald weefselbiopt door middel van het wassen van het biopt (Core Wash: CW) 
danwel het biopt tegen een glaasje aan te drukken (Touch Imprint: TI). In het laboratorium 
ontvangen, niet-formaldehyde gefixeerde borstweefselresectie preparaten met haardvormige 
afwijkingen werden gebiopteerd met een 18-gauge holle naald, en van het biopsie materiaal 
werden TI en CW glaasjes voor cytologische beoordelingen gemaakt. De diagnosen werden 
gecategoriseerd als: onvoldoende diagnostische cellen/materiaal (C1), benigne (C2), atypie 
(C3), verdacht voor maligniteit (C4) of maligne (C5) en vergeleken met de histologische 
resultaten van de CNB. De studie toonde slechts een klein verschil aan in de resultaten tussen 
CW en TI cytologie. Echter, vanwege de betere morfologie en de voordelen van de 
'dunnelaag' techniek werd gekozen voor de CW techniek, welke vervolgens werd ingevoerd in 
de klinische praktijk.
De eerste klinische gegevens over de CW diagnostiek worden gepresenteerd in hoofdstuk 7. 
De resultaten van de CW cytologie en de CNB histologie, verkregen van 226 afwijkingen in 
de borst, werden vergeleken met de histologische resultaten van de later verkregen resectie 
preparaten. De CW cytologie resulteerde in een goede sensitiviteit en specificiteit in 
vergelijking met de histologische diagnose van het resectie preparaat. De applicatie van de 
gemodificeerde CW cytologie techniek kan zorgen voor een betrouwbare indicatie van de 
verwachte CNB diagnose en daarmee een waardevol instrument zijn bij het plannen van 
verder vervolgonderzoek en behandeling van patiënten die een 'zelfde-dag-borstkliniek' 
bezoeken.
Hoofdstuk 8 beschrijft een onderzoek waarbij in een retrospectieve studie, de waarde van het 
cytologisch onderzoek van het hersenvocht (liquor) bij patiënten bekend met borstkanker en 
bij wie neurologische klachten werden vastgesteld. Bij een substantieel aantal patiënten met 
neurologische symptomen, maar zonder radiologische afwijkingen, werden kwaadaardige
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cellen in de liquor aangetroffen. In tegenspraak met de literatuur was de toegevoegde waarde 
van herhaald cytologisch onderzoek van de liquor zeer beperkt. De studie onderstreept dat 
liquor cytologie een waardevol instrument is voor een eenduidige diagnose van de 
metastatische verspreiding van borstkanker naar het centraal zenuwstelsel. Het vaststellen van 
kwaadaardige cellen in de liquor bleek een sterke voorspeller te zijn voor een korte 
overleving.
Wij zijn ons bewust van de controverse over de rol van cytologisch onderzoek in de 
diagnostiek van borstafwijkingen in het algemeen en in het bijzonder van niet-palpabele 
borstafwijkingen. Gebaseerd op de studies beschreven in dit proefschrift kunnen we 
concluderen dat cytologisch onderzoek een snelle en betrouwbare diagnose biedt bij veel 
patiënten en daarom nog steeds een waardevolle steun is in de diagnostiek van patiënten met 
borstafwijkingen, vooral in de 'zelfde-dag-borstkliniek' waarin ultra-snelle verwerking van 
biopten voor histologische analyse niet (altijd) beschikbaar is. Andere voordelen van de 
cytologische analyse zijn: het is relatief goedkoop en technisch eenvoudig uit te voeren. 
Echter, voor een optimale bereiding en evaluatie van de cytologische preparaten van de 
borstafwijkingen is geschoold personeel van cruciaal belang, verder is de cytologische 
diagnose veelal minder specifiek dan de histologische diagnose die gesteld wordt op biopsie 
materiaal (bv. 'carcinoom' op basis van cytologisch onderzoek versus type kanker en 
maligniteitsgraad op basis van histologische analyse). Bovendien laat een puur cytologische 
benadering veelal weinig materiaal over voor extra immunocytochemische en/of moleculair 
onderzoekn. Een belangrijke bevinding in dit proefschrift is dat een snelle cytologische 
analyse kan worden gecombineerd met het histologisch onderzoek van een dikke naald 
biopsie van een borstafwijking, zonder dat de kwaliteit van de histologische diagnose wordt 
aangetast. Daardoor kan diagnostiek en het verder plannen van behandeling van de patiënt in 
een 'zelfde-dag-borstkliniek', beter worden vormgegeven.
We concluderen derhalve dat cytologisch onderzoek nog steeds een zeer waardevol 
instrument is in de diagnostiek en behandeling van patiënten met laesies in de borst / 
borstkanker, en dat het belangrijk is om het hoge niveau van de diagnostische vaardigheden 
op dit gebied te handhaven.
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Een proefschrift is het concrete eindresultaat van het werk van een promovendus en kan 
alleen tot stand komen met de hulp van vele anderen. Op deze plaats wil ik mijn grote 
waardering en dank uitspreken aan allen die mij ter wille zijn geweest bij het onderzoek en 
het schrijven van dit proefschrift. Een aantal van hen wil ik met name noemen.
Luc Strobbe; beste collega en vriend Luc, we hadden het er al eerder over gehad dat het wel 
heel goed zou zijn als we een databank zouden kunnen samenstellen van alle 
gediagnostiseerde mamma-lesies van de laatste 20 jaar in het CWZ. Maar ja, waar moesten 
we de tijd vandaan halen. Toen eind 2007 student-assistent geneeskunde Bauke Kooistra bij 
jou aanklopte met het verzoek onderzoek te doen hadden we iemand voor het opzetten van 
zo'n databank gevonden!
Dat het de aanzet zou worden voor een proefschrift hadden we aanvankelijk niet bedacht. 
Luc, jij bent zeer wetenschappelijk geïnteresseerd en ingesteld, ik ben dan ook al je  zoveelste 
promovendus. Heel veel dank voor het meedenken en ondersteunen van het verrichtte werk. 
Je was een fantastisch klankbord ook al was je vaak niet zo gecharmeerd van mijn ‘(te) lange 
zinnen’.Ook veel dank voor de relativerende, vaak bijna filosofische gesprekken die we, waar 
dan ook ter wereld, samen hebben gehad.
Bauke Kooistra; beste Bauke, voor jou was het onderzoekstraject eerst een beetje schrikken; 
je wilde onderzoek doen binnen de chirurgie en kwam terecht op een afdeling Pathologie. 
Vanuit een dynamische afdeling werd je doorgesluisd naar een, toendertijd in ieder geval in 
jouw ogen, statische afdeling. Doch, je  hebt je mening daaromtrent bijgesteld. Jammer genoeg
hebben we je nog niet ‘kunnen strikken voor de pathologie’. Maar wie weet.....
Door jou voortvarende inzet en grote kundigheid en handigheid om de databank vorm te 
geven, konden al snel antwoorden op de eerste vraagstellingen gegenereerd worden. Het was 
zeer plezierig en stimulerend om met jou onderzoek te doen. Bijzonder dat het voor ons beide 
uiteindelijk heeft geresulteerd in een proefschrift.
Pieter Wesseling; beste Pieter, verbazing, was je eerste reactie, op mijn vraag of je de 
promotor van mijn proefschrift zou willen zijn. Ik had wel de wens dat we ook een artikel 
zouden schrijven over het naar het centraal zenuwstelsel gemetastaseerde mammacarcinoom. 
Vrij snel stemde je toe. Onze collegiale samenwerking kreeg vanaf dat moment ook een 
intensieve en heel inspirerende wetenschappelijke dimensie. Heel veel dank voor je zeer grote 
inzet en vooral voor het kritisch doornemen van de stukken. Dit laatste viel soms niet mee, 
maar ik heb er veel van geleerd èn het manuscript is er keer op keer beter van geworden.
Marcel Mravunac; beste Marcel, als eerste patholoog in Nederland implementeerde jij de 
dunne laag cytologie in de diagnostiek van borstafwijkingen. Na een lange testfase met goede 
resultaten werd de uitstrijkmethode verlaten. De eerste studie is eigenlijk (nogmaals) een 
bevestiging dat het toentertijd een goede beslissing was. Zonder jouw hang naar voortdurende 
vernieuwingen en verbeteringen in de diagnostiek (op trouwens alle gebied binnen ons vak) 
zou deze studie niet tot stand gekomen zijn. Bovenal was je een zeer kundig èn prettig 
collega. Een collega op wie je altijd een beroep kon doen, ook nog vele jaren na je 
pensionering.
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Mieke Sanders-Eras; beste Mieke, ik wil je  vooral danken voor je grote inzet binnen de core 
wash cytology (CWC) studies. Het was jou idee om de biopten te ‘gaan wassen in RPMI’. Het 
leverde ons fraaie resultaten op in de laboratorium- en de techniek werd geïmplementeerd in 
de kliniek. De CWC is in het CWZ een begrip geworden in de ‘zelfde-dag-borstkliniek’ en 
past goed in de up-to-date diagnostiek van borst afwijkingen bij de vrouw en de man.
Janneke Poelen; beste Janneke, veel dank ben ik jou verschuldigd voor het verzamelen van de 
klinische gegevens voor de databank van de studie betreffende het naar het centraal 
zenuwstelsel gemetastaseerde mammacarcinoom. Deze studie is ook een start van jouw 
promotietraject. Hopelijk gaan er nog meer artikelen uit deze databank komen en kunnen we 
onze plezierige en opbouwende wetenschappelijke samenwerking voortzetten.
Chantal Huyben-van Leent; beste Chantal, mijn steun en toeverlaat op Excel-, Word- en 
Powerpoint-gebied. Door jouw grote inzet waren de patiëntgegevens voor de ‘male breast 
study’, de ‘CWC studies’ en ‘CSF-studie’ binnen de kortste tijd in een Excel bestand gezet. Je 
stond altijd voor me klaar, zelfs op de dagen die je voor de kleine Kirsten gereserveerd had. 
Veel dank voor je bijdrage aan het tot stand komen van dit boekwerk.
Mijn collega pathologen: Saskia van den Berg-van Erp, Heidi Küsters-Vandevelde, Willem 
Vreuls, Saskia Zomer, Ineke de Kievit- van der Heijden en Theo Manschot en mijn 
management rechter- (of toch linker?) hand Gé Verbeet; jullie wil ik hartelijk danken voor het 
meedenken, meelezen, motiveren en ondersteunen van het onderzoekswerk en het 
vervaardigen van dit proefschrift. Vreugde (geaccepteerde stukken) en tegenvallers (mislukte 
testen, verdwenen informatie in databanken etc.) kon ik met jullie delen. Heel veel dank 
hiervoor!
Medewerkers afdeling pathologie CWZ; beste allemaal, allemaal hebben jullie óók jullie 
steentje bijgedragen in dit werk. De verwerking van de cytologische en histologische glaasjes 
en coupes van de CWC-lab-studie is grotendeels tussen de bedrijven door gegaan, ook al was 
er die dag veel andere diagnostiek. Ook dank voor de flexibele opstelling in de uitsnijkamer 
als Mieke of ik weer een keer ‘in de weg’ kwamen staan voor de afname van de biopten. Zo 
ook dank aan Roel Besseling, Ronald van den Kieboom en Marco van Beers voor de 
ondersteuning in het maken van lastige tabellen en lay out problematiek in Word.
Erik van Haaren; beste Erik, ik wil je danken voor het telkens weer zeer vlot aanleveren van 
de door mij opgevraagde artikelen.
Mijn paranimfen Cecile de Mol en Lies Jaspars; lieve Ciel en Lies, vriendinnen van, 
respectievelijk, het eerste uur in de geneeskunde (1978) en in de pathologie (1999). Ook al 
zien we elkaar niet vaak, áls we elkaar spreken leek het laatste contact gisteren. Met vol 
enthousiasme doken jullie in deze nieuwe functie. Dank voor jullie onvoorwaarlijke inzet in 
het meedenken, organiseren en ondersteunen van de feestelijkheden.
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Inge Coveen; mijn lieve vriendin en jaargenoot Inge, eigenlijk wil ik dit proefschrift ook een 
beetje aan haar opdragen. Als ze nu geleefd zou hebben waren haar kansen op overleving veel 
groter geweest dan 17 jaar geleden. (op 34 jarige leeftijd overleden aan de gevolgen van een 
gemetastaseerd mammacarcinoom)
Ursula Scholten; ook mijn lieve vriendin Ursula wil ik hier vermelden. Ze was een zeer 
kundig amateur-fotografe die al vele feestjes van ons fotografisch heeft verzorgd. Ook voor 
de promotie ‘eiste’ ze haar plek weer op. Echter in september vorig jaar hebben we 
onverwacht afscheid moeten nemen van deze zeer energieke en lieve dame. Het zou zo niet 
mogen zijn: met vrienden moet je oud kunnen worden.
Mijn lieve jongens thuis, Marcel en Pieter, sluiten de rij. Lieve Marcel, eigenlijk kan ik een 
heel hoofdstuk schrijven over jouw ‘values’, maar ‘that's beyond the scope of this thesis’. 
Lieverd, ik dank je voor je niet-aflatende steun, met name aan het eind toen het toch allemaal 
wat zwaarder werd dan ik had ingeschat. Lieve Pieter, van nu af aan zullen je Donald Ducks 
niet meer tussen de wetenschappelijke artikelen op de eetkamertafel zoek raken en zal je 
mama 's  ochtends voor het ontbijt niet meer beneden achter de PC aantreffen. Misschien wil 
ze van nu af aan wel ontbijt op bed, door jou geserveerd!
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Carla (Carolina Alphonsina Petronella) Wauters is geboren op 29 maart 1957 te Hulst in 
Zeeuws-Vlaanderen, Zeeland. In Hulst heeft zij het Atheneum B aan de Jansenius 
Scholengemeenschap gevolgd. In 1978 werd aangevangen met de studie Geneeskunde aan de 
Rijks Universiteit te Utrecht, deze studie werd afgerond in 1986. Vervolgens was zij tussen 
1986 en 1989 werkzaam als assistent-niet-in-opleiding (agnio) op de afdeling Algemene 
Heelkunde in het St. Antonius Ziekenhuis te Nieuwegein en op de afdelingen KNO en 
Heelkunde in het Antoni van Leeuwenhoek Ziekenhuis te Amsterdam (op laatstgenoemde 
afdeling met focus op borstkanker).
In 1989 werd Carla Wauters aangesteld als agnio Pathologie in het Diagnostisch Centrum 
SSDZ te Delft. In deze periode heeft zij o.a. een kortdurende uitstap gemaakt naar de afdeling 
Pathologie van het Academisch Medisch Centrum te Amsterdam. In 1990 startte zij met de 
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